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1. SUPPLEMENTARY TABLES 
Supplementary Table 1. Sample sizes for summary-level GWAS data used for analysis of 14 cancers.  
Groupa Cancer site 
Number of SNPs 
analyzed after 
filtering in the 
model 
Number of cases Number of controls Chip imputation Information 
1 
CLLb1 1,068,036 3,100 7,667 Infor score >0.3 
Esophagealc2 1,068,728 3,914 6,718 Info score >0.4 
Testicular3 1,066,591 3,558 13,970 Info score >0.3 
Oropharyngeal4 1,067,193 6,034 6,585 Call rate >98% 
Pancreas5 915,805 8,638 12,217 Info >0.3 
2 
Renal6 1,067,952 10,784 20,407 Info >0.3 
Glioma7 1,067,960 12,488 18,169 Info >0.4 
Melanoma8 1,052,042 12,874 23,203 Quality R^2>0.95 
Colorectal9 1,058,067 17,050 19,529 Call rate >95%, R^2 >0.7 
Endometrial10 1,068,132 12,906 108,979 Info score>0.4 
Ovarian11 1,068,810 22,406 40,951 Call rate >95% 
3 
Lung12 1,009,906 29,266 56,450 R^2>0.3, info >0.4 
Prostate13 806,185 79,148 61,106 R^2>0.8 
Breast14 1,067,502 108,067 88,386 Info score >0.3 
aGroup 1, group 2, and group 3 include <10K, 10-25K, and >25K cases in the analysis, respectively. bCLL = chronic lymphocytic leukemia. 
cIncludes Barrett’s esophagus and esophageal adenocarcinoma cases. 
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Supplementary Table 2. Number of independent genome-wide significant SNPs (p< 𝟓 × 𝟏𝟎!𝟖) and 
associated heritability explained in the current datasets and those projected based on the estimated 
effect-size distribution using sample sizes of the current datasets. The number of independent SNPs 
reaching genome-wide significance in current studies were based on LD-clumping with an 𝑟#-threhold of 
0.1 and 1 MB window size. The heritability explained (ℎ$#)	associated with these SNPs were calculated 
using the formula ℎ$# = ∑ (𝛽-%# − 𝜏%#)%  where 𝛽-%  is the estimate of log-odds-ratio (in standardized scale) 
















GENESIS projection of 
𝒉𝐞𝟐 of the genome-
wide significant SNPs 
(95%CI) 
CLLa 20 0.559 16 (8, 29) 0.53 (0.31, 0.83) 
Esophageal 1 0.012 0 (0, 5) 0.00 (0.00, 0.03) 
Testicular 38 0.908 44 (28, 79) 1.10 (0.81, 1.59) 
Oropharyngeal 0 0.000 0 (NA) 0.00 (NA) 
Pancreas 11 0.128 11 (5, 25) 0.13 (0.07, 0.24) 
Renal 16 0.116 12 (5, 28) 0.10 (0.05, 0.17) 
Glioma 33 0.488 22 (13, 35) 0.44 (0.33, 0.55) 
Melanoma 26 0.265 28 (16, 48) 0.27 (0.20, 0.36) 
Colorectal 8 0.039 8 (3, 19) 0.03 (0.01, 0.08) 
Endometrial 13 0.047 12 (5, 34) 0.05 (0.03, 0.12) 
Ovarian 12 0.056 16 (7, 34) 0.07 (0.04, 0.12) 
Lung 15 0.066 8 (3, 18) 0.06 (0.04, 0.08) 
Prostate 144 0.392 127 (102, 169) 0.37 (0.33, 0.41) 
Breast 169 0.278 149 (120, 192) 0.27 (0.24, 0.29) 








Supplementary Figure 1. Q-Q plots comparing observed distributions of GWAS summary statistics 
against those expected under the fitted GENESIS models across 8 different cancers. X-axis represents 
expected −log&'(p-value), and y-axis represent observed −log&'(p-value). Plots in upper and lower 
panels are generated under the two- and three-component models, respectively. The two-component 
model assumes the non-null effect sizes to follow a single normal distribution. The three-component 
model assumes the non-null effect sizes to follow a mixture of two normal distributions with two distinct 
variance components. Shaded regions mark 80% point-wise confidence intervals derived from 100 
simulations. 𝜆()* is the genomic control factor in the observed summary-level GWAS data; 𝜆+,- is the 
mean genomic control factor in simulated data over 100 replications. The ranges for all plots are 
restricted to be p-value < 10!&'. CLL = chronic lymphocytic leukemia.  
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Supplementary Figure 2. Q-Q plots comparing observed distributions of GWAS summary statistics 
against those expected under the fitted GENESIS models across 6 different cancers. X-axis represents 
expected −log&'(p-value), and y-axis represent observed −log&'(p-value). Plots in upper and lower 
panels are generated under the two- and three-component models, respectively. The two-component 
model assumes the non-null effect sizes to follow a single normal distribution. The three-component 
model assumes the non-null effect sizes to follow a mixture of two normal distributions with two distinct 
variance components. Shaded regions mark 80% point-wise confidence intervals derived from 100 
simulations. 𝜆()* is the genomic control factor in the observed summary-level GWAS data; 𝜆+,- is the 
mean genomic control factor in simulated data over 100 replications. The ranges for all plots are 





Supplementary Figure 3. Projections of area under the curve (AUC) characterizing predictive 
performance of PRS as sample size for GWAS increases. Results are shown for PRS including SNPs at the 
optimized p-value threshold (solid curve) and at genome-wide significance (p<5 × 10!.) level (dashed 
curve). The dotted horizontal red line indicates the maximum AUC achievable according to the estimate 
of GWAS heritability. Colored dots correspond to sample size for largest published GWAS and those for 
doubled and quadruped sizes.  For oropharyngeal cancer, the projections at the “current sample size” are based on a sample size of 
25K cases and 25K controls. For breast and esophageal cancer, the projections at the “current sample size” are based on the current largest 
GWAS sample sizes: 123K cases and 106K controls, and 10K cases and 17K controls, respectively. For all other cancer sites, the projections at 
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Supplementary Figure 4. Projections of relative risks for individuals at or higher than 99th percentile of 
PRS distribution (compared to average risk) as sample size for GWAS increases. Results are shown for 
PRS including SNPs at the optimized p-value threshold (solid curve) and at genome-wide significance 
(p<5 × 10!.) level (dashed curve). The dotted horizontal red line indicates the maximum relative risk 
achievable according to estimate of GWAS heritability. Colored dots correspond to sample size for 
largest published GWAS and those for doubled and quadruped sizes. Y-axis is presented in log10 scale. 
For oropharyngeal cancer, the projections at the “current sample size” are based on a sample size of 25K cases and 25K controls. For breast and 
esophageal cancer, the projections at the “current sample size” are based on the current largest GWAS sample sizes: 123K cases and 106K 
controls, and 10K cases and 17K controls, respectively. For all other cancer sites, the projections at the “current sample size” are based on the 
GWAS sample sizes in Supplementary Table 1. CLL = chronic lymphocytic leukemia. 
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Supplementary Figure 5. Projected distribution of age-stratified residual lifetime risk (up to age 75) in 
US Non-Hispanic Whites according to variation of polygenic risk scores (group 1 cancers). Colored 
shades correspond to sample size for largest published GWAS and those for doubled, quadruped and 
infinite sizes. For oropharyngeal cancer, the projections at the “current sample size” are based on a sample size of 25K cases and 25K 
controls. For esophageal cancer, the projections at the “current sample size” are based on the current largest GWAS sample sizes: 10K cases 
and 17K controls. For all other cancer sites, the projections at the “current sample size” are based on the GWAS sample sizes in Supplementary 





Supplementary Figure 6. Projected distribution of age-stratified residual lifetime risk (up to age 75) in 
US Non-Hispanic Whites according to variation of polygenic risk scores (group 2 cancers). Colored 
shades correspond to sample size for largest published GWAS and those for doubled, quadruped and 




Supplementary Figure 7. Projected distribution of age-stratified residual lifetime risk (up to age 75) in 
US Non-Hispanic Whites according to variation of polygenic risk scores (group 3 cancers). Colored 
shades correspond to sample size for largest published GWAS and those for doubled, quadruped and 
infinite sizes. For breast cancer, the projections at the “current sample size” are based on the current largest GWAS sample sizes: 123K 
cases and 106K controls. For all other cancer sites, the projections at the “current sample size” are based on the GWAS sample sizes 
in Supplementary Table 1. 
  
 11 
3. SUPPLEMENTARY NOTE 
3.1 CONSORTIUM-SPECIFIC FUNDING AND ACKNOWLEDGEMENTS 
BCAC 
Funding: 
BCAC is funded by Cancer Research UK [C1287/A16563, C1287/A10118], the European Union's Horizon 
2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST 
respectively), and by the European Community´s Seventh Framework Programme under grant 
agreement number 223175 (grant number HEALTH-F2-2009-223175) (COGS). The EU Horizon 2020 
Research and Innovation Programme funding source had no role in study design, data collection, data 
analysis, data interpretation or writing of the report. 
 
Genotyping of the OncoArray was funded by the NIH Grant U19 CA148065, and Cancer UK Grant 
C1287/A16563 and the PERSPECTIVE project supported by the Government of Canada through Genome 
Canada and the Canadian Institutes of Health Research (grant GPH-129344) and, the Ministère de 
l’Économie, Science et Innovation du Québec through Genome Québec and the PSRSIIRI-701 grant, and 
the Quebec Breast Cancer Foundation. Funding for the iCOGS infrastructure came from: the European 
Community's Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-
223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, 
C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health 
(CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - 
the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of 
Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer,  and Komen Foundation for 
the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. The DRIVE 
Consortium was funded by U19 CA148065. 
 
The Australian Breast Cancer Family Study (ABCFS)was supported by grant UM1 CA164920 from the 
National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or 
policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family 
Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply 
endorsement by the USA Government or the BCFR. The ABCFS was also supported by the National 
Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian 
Health Promotion Foundation (Australia) and the Victorian Breast Cancer Research Consortium. J.L.H. is 
a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow. M.C.S. is a 
NHMRC Senior Research Fellow. The ABCS study was supported by the Dutch Cancer Society [grants NKI 
2007-3839; 2009 4363]. The Australian Breast Cancer Tissue Bank (ABCTB) was supported by the 
National Health and Medical Research Council of Australia, The Cancer Institute NSW and the National 
Breast Cancer Foundation. The ACP study is funded by the Breast Cancer Research Trust, UK. The work 
of the BBCC was partly funded by ELAN-Fond of the University Hospital of Erlangen. The BBCS is funded 
by Cancer Research UK and Breast Cancer Now and acknowledges NHS funding to the NIHR Biomedical 
Research Centre, and the National Cancer Research Network (NCRN). The BCEES was funded by the 
National Health and Medical Research Council, Australia and the Cancer Council Western Australia and 
acknowledges funding from the National Breast Cancer Foundation (JS). For the BCFR-NY, BCFR-PA, 
BCFR-UT this work was supported by grant UM1 CA164920 from the National Cancer Institute. The 
content of this manuscript does not necessarily reflect the views or policies of the National Cancer 
Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does 
mention of trade names, commercial products, or organizations imply endorsement by the US 
Government or the BCFR. For BIGGS, ES is supported by NIHR Comprehensive Biomedical Research 
Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London, United 
Kingdom. IT is supported by the Oxford Biomedical Research Centre. BOCS is supported by funds from 
Cancer Research UK (C8620/A8372/A15106) and the Institute of Cancer Research (UK). 
BOCSacknowledges NHS funding to the Royal Marsden / Institute of Cancer Research NIHR Specialist 
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Cancer Biomedical Research Centre. The BREast Oncology GAlician Network (BREOGAN) is funded by 
Acción Estratégica de Salud del Instituto de Salud Carlos III FIS PI12/02125/Cofinanciado FEDER; Acción 
Estratégica de Salud del Instituto de Salud Carlos III FIS Intrasalud (PI13/01136); Programa Grupos 
Emergentes, Cancer Genetics Unit, Instituto de Investigacion Biomedica Galicia Sur. Xerencia de Xestion 
Integrada de Vigo-SERGAS, Instituto de Salud Carlos III, Spain; Grant 10CSA012E, Consellería de Industria 
Programa Sectorial de Investigación Aplicada, PEME I + D e I + D Suma del Plan Gallego de Investigación, 
Desarrollo e Innovación Tecnológica de la Consellería de Industria de la Xunta de Galicia, Spain; Grant 
EC11-192. Fomento de la Investigación Clínica Independiente, Ministerio de Sanidad, Servicios Sociales e 
Igualdad, Spain; and Grant FEDER-Innterconecta. Ministerio de Economia y Competitividad, Xunta de 
Galicia, Spain. The BSUCH studywas supported by the Dietmar-Hopp Foundation, the Helmholtz Society 
and the German Cancer Research Center (DKFZ). CBCS is funded by the Canadian Cancer Society (grant # 
313404) and the Canadian Institutes of Health Research. CCGP is supported by funding from the 
University of Crete. The CECILE study was supported by Fondation de France, Institut National du Cancer 
(INCa), Ligue Nationale contre le Cancer, Agence Nationale de Sécurité Sanitaire, de l'Alimentation, de 
l'Environnement et du Travail (ANSES), Agence Nationale de la Recherche (ANR). The CGPS was 
supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research 
Council, and Herlev and Gentofte Hospital. The American Cancer Society funds the creation, 
maintenance, and updating of the CPS-II cohort. The CTS was initially supported by the California Breast 
Cancer Act of 1993 and the California Breast Cancer Research Fund (contract 97-10500) and is currently 
funded through the National Institutes of Health (R01 CA77398, UM1 CA164917, and U01 CA199277). 
Collection of cancer incidence data was supported by the California Department of Public Health as part 
of the statewide cancer reporting program mandated by California Health and Safety Code Section 
103885. HAC receives support from the Lon V Smith Foundation (LVS39420). The University of 
Westminster curates the DietCompLyf database funded by Against Breast Cancer Registered Charity No. 
1121258 and the NCRN. The coordination of EPIC is financially supported by the European Commission 
(DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported 
by:  Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut 
National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German 
Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the 
Hellenic Health Foundation, the Stavros Niarchos Foundation (Greece); Associazione Italiana per la 
Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, 
Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention 
Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics 
Netherlands (The Netherlands); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-
Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC 
(RD06/0020) (Spain); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to 
EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) 
(United Kingdom). The ESTHER study was supported by a grant from the Baden Württemberg Ministry 
of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study, which 
was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). FHRISK is funded from 
NIHR grant PGfAR 0707-10031. The GC-HBOC (German Consortium of Hereditary Breast and Ovarian 
Cancer) is supported by the German Cancer Aid (grant no 110837, coordinator: Rita K. Schmutzler, 
Cologne). This work was also funded by the European Regional Development Fund and Free State of 
Saxony, Germany (LIFE - Leipzig Research Centre for Civilization Diseases, project numbers 713-241202, 
713-241202, 14505/2470, 14575/2470). The GENICA was funded by the Federal Ministry of Education 
and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114, the 
Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, the 
Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of 
the Ruhr University Bochum (IPA), Bochum, as well as the Department of Internal Medicine, 
Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. The GEPARSIXTO study 
was conducted by the German Breast Group GmbH. The GESBC was supported by the Deutsche 
Krebshilfe e. V. [70492] and the German Cancer Research Center (DKFZ). The HABCS study was 
supported by the Claudia von Schilling Foundation for Breast Cancer Research, by the Lower Saxonian 
Cancer Society, and by the Rudolf Bartling Foundation. TheHEBCS was financially supported by the 
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Helsinki University Hospital Research Fund, the Finnish Cancer Society, and the Sigrid Juselius 
Foundation. TheHERPACC was supported by MEXT Kakenhi (No. 170150181 and 26253041) from the 
Ministry of Education, Science, Sports, Culture and Technology of Japan, by a Grant-in-Aid for the Third 
Term Comprehensive 10-Year Strategy for Cancer Control from Ministry Health, Labour and Welfare of 
Japan, by Health and Labour Sciences Research Grants for Research on Applying Health Technology from 
Ministry Health, Labour and Welfare of Japan, by National Cancer Center Research and Development 
Fund, and "Practical Research for Innovative Cancer Control (15ck0106177h0001)" from Japan Agency 
for Medical Research and development, AMED, and Cancer Bio Bank Aichi. The HMBCSwas supported by 
a grant from the Friends of Hannover Medical School and by the Rudolf Bartling Foundation. The 
HUBCSwas supported by a grant from the German Federal Ministry of Research and Education 
(RUS08/017), and by the Russian Foundation for Basic Research and the Federal Agency for Scientific 
Organizations for support the Bioresource collections and RFBR grants 14-04-97088, 17-29-06014 and 
17-44-020498. ICICLE was supported by Breast Cancer Now, CRUK and Biomedical Research Centre at 
Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. Financial support for KARBAC 
was provided through the regional agreement on medical training and clinical research (ALF) between 
Stockholm County Council and Karolinska Institutet, the Swedish Cancer Society, The Gustav V Jubilee 
foundation and Bert von Kantzows foundation. The KARMA study was supported by Märit and Hans 
Rausings Initiative Against Breast Cancer. The KBCP was financially supported by the special Government 
Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer 
Organizations, and by the strategic funding of the University of Eastern Finland. The KOHBRA study was 
partially supported by a grant from the Korea Health Technology R&D Project through the Korea Health 
Industry Development Institute (KHIDI), and the National R&D Program for Cancer Control, Ministry of 
Health & Welfare, Republic of Korea (HI16C1127; 1020350; 1420190). LMBC is supported by the 
'Stichting tegen Kanker'. DL is supported by the FWO. The MABCS study is funded by the Research 
Centre for Genetic Engineering and Biotechnology "Georgi D. Efremov", MASA. The MARIE study was 
supported by the Deutsche Krebshilfe e.V. [70-2892-BR I, 106332, 108253, 108419, 110826, 110828], 
the Hamburg Cancer Society, the German Cancer Research Center (DKFZ) and the Federal Ministry of 
Education and Research (BMBF) Germany [01KH0402]. MBCSG is supported by grants from the Italian 
Association for Cancer Research (AIRC) and by funds from the Italian citizens who allocated the 5/1000 
share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to 
Italian laws (INT-Institutional strategic projects “5x1000”). The MCBCS was supported by the NIH grants 
CA192393, CA116167, CA176785 an NIH Specialized Program of Research Excellence (SPORE) in Breast 
Cancer [CA116201], and the Breast Cancer Research Foundation and a generous gift from the David F. 
and Margaret T. Grohne Family Foundation. The Melbourne Collaborative Cohort Study (MCCS) cohort 
recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further augmented by 
Australian National Health and Medical Research Council grants 209057, 396414 and 1074383 and by 
infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through 
the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National 
Death Index and the Australian Cancer Database. The MEC was support by NIH grants CA63464, 
CA54281, CA098758, CA132839 and CA164973. The MISS study is supported by funding from ERC-2011-
294576 Advanced grant, Swedish Cancer Society, Swedish Research Council, Local hospital funds, Berta 
Kamprad Foundation, Gunnar Nilsson. The MMHS study was supported by NIH grants CA97396, 
CA128931, CA116201, CA140286 and CA177150. MSKCC is supported by grants from the Breast Cancer 
Research Foundation and Robert and Kate Niehaus Clinical Cancer Genetics Initiative. The work of 
MTLGEBCS was supported by the Quebec Breast Cancer Foundation, the Canadian Institutes of Health 
Research for the “CIHR Team in Familial Risks of Breast Cancer” program – grant # CRN-87521 and the 
Ministry of Economic Development, Innovation and Export Trade – grant # PSR-SIIRI-701. MYBRCA is 
funded by research grants from the Malaysian Ministry of Higher Education (UM.C/HlR/MOHE/06) and 
Cancer Research Malaysia. The NBCS has received funding from the K.G. Jebsen Centre for Breast Cancer 
Research; the Research Council of Norway grant 193387/V50 (to A-L Børresen-Dale and V.N. Kristensen) 
and grant 193387/H10 (to A-L Børresen-Dale and V.N. Kristensen), South Eastern Norway Health 
Authority (grant 39346 to A-L Børresen-Dale) and the Norwegian Cancer Society (to A-L Børresen-Dale 
and V.N. Kristensen). The NBHS was supported by NIH grant R01CA100374. Biological sample 
preparation was conducted the Survey and Biospecimen Shared Resource, which is supported by P30 
 14 
CA68485. The Northern California Breast Cancer Family Registry (NC-BCFR) and Ontario Familial Breast 
Cancer Registry (OFBCR) were supported by grant UM1 CA164920 from the National Cancer Institute 
(USA). The content of this manuscript does not necessarily reflect the views or policies of the National 
Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does 
mention of trade names, commercial products, or organizations imply endorsement by the USA 
Government or the BCFR. The NGOBCS was supported by Grants-in-Aid for the Third Term 
Comprehensive Ten-Year Strategy for Cancer Control from the Ministry of Health, Labor and Welfare of 
Japan, and for Scientific Research on Priority Areas, 17015049 and for Scientific Research on Innovative 
Areas, 221S0001, from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The 
NHS was supported by NIH grants P01 CA87969, UM1 CA186107, and U19 CA148065. The NHS2 was 
supported by NIH grants UM1 CA176726 and U19 CA148065. The ORIGO study was supported by the 
Dutch Cancer Society (RUL 1997-1505) and the Biobanking and Biomolecular Resources Research 
Infrastructure (BBMRI-NL CP16). The PBCS was funded by Intramural Research Funds of the National 
Cancer Institute, Department of Health and Human Services, USA. Genotyping for PLCO was supported 
by the Intramural Research Program of the National Institutes of Health, NCI, Division of Cancer 
Epidemiology and Genetics.  The PLCO is supported by the Intramural Research Program of the Division 
of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer 
Prevention, National Cancer Institute, National Institutes of Health. The POSH study is funded by Cancer 
Research UK (grants C1275/A11699, C1275/C22524, C1275/A19187, C1275/A15956 and Breast Cancer 
Campaign 2010PR62, 2013PR044. PROCAS is funded from NIHR grant PGfAR 0707-10031. The RBCS was 
funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). The SASBAC study was 
supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the 
US National Institute of Health (NIH) and the Susan G. Komen Breast Cancer Foundation. The SBCGS was 
supported primarily by NIH grants R01CA64277, R01CA148667, UMCA182910, and R37CA70867. 
Biological sample preparation was conducted the Survey and Biospecimen Shared Resource, which is 
supported by P30 CA68485. The scientific development and funding of this project were, in part, 
supported by the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network U19 
CA148065. SEARCH is funded by Cancer Research UK [C490/A10124, C490/A16561] and supported by 
the UK National Institute for Health Research Biomedical Research Centre at the University of 
Cambridge. The University of Cambridge has received salary support for PDPP from the NHS in the East 
of England through the Clinical Academic Reserve. SEBCS was supported by the BRL (Basic Research 
Laboratory) program through the National Research Foundation of Korea funded by the Ministry of 
Education, Science and Technology (2012-0000347). SGBCC is funded by the NUS start-up Grant, 
National University Cancer Institute Singapore (NCIS) Centre Grant and the NMRC Clinician Scientist 
Award. Additional controls were recruited by the Singapore Consortium of Cohort Studies-Multi-ethnic 
cohort (SCCS-MEC), which was funded by the Biomedical Research Council, grant number: 
05/1/21/19/425. The Sister Study (SISTER) is supported by the Intramural Research Program of the NIH, 
National Institute of Environmental Health Sciences (Z01-ES044005 and Z01-ES049033). The Two Sister 
Study (2SISTER) was supported by the Intramural Research Program of the NIH, National Institute of 
Environmental Health Sciences (Z01-ES044005 and Z01-ES102245), and, also by a grant from Susan G. 
Komen for the Cure, grant FAS0703856. SKKDKFZS is supported by the DKFZ. The SMC is funded by the 
Swedish Cancer Foundation and the Swedish Research Council (VR 2017-00644) grant for the Swedish 
Infrastructure for Medical Population-based Life-course Environmental Research (SIMPLER). The SZBCS 
was supported by Grant PBZ_KBN_122/P05/2004. The TNBCC was supported by: a Specialized Program 
of Research Excellence (SPORE) in Breast Cancer (CA116201), a grant from the Breast Cancer Research 
Foundation, a generous gift from the David F. and Margaret T. Grohne Family Foundation. The TWBCS is 
supported by the Taiwan Biobank project of the Institute of Biomedical Sciences, Academia Sinica, 
Taiwan. The UCIBCS component of this research was supported by the NIH [CA58860, CA92044] and the 
Lon V Smith Foundation [LVS39420]. The UKBGS is funded by Breast Cancer Now and the Institute of 
Cancer Research (ICR), London. ICR acknowledges NHS funding to the NIHR Biomedical Research Centre. 
The UKOPS study was funded by The Eve Appeal (The Oak Foundation) and supported by the National 
Institute for Health Research University College London Hospitals Biomedical Research Centre. The 
US3SS study was supported by Massachusetts (K.M.E., R01CA47305), Wisconsin (P.A.N., R01 CA47147) 
and New Hampshire (L.T.-E., R01CA69664) centers, and Intramural Research Funds of the National 
 15 
Cancer Institute, Department of Health and Human Services, USA. The WHI program is funded by the 
National Heart, Lung, and Blood Institute, the US National Institutes of Health and the US Department of 
Health and Human Services (HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, 
HHSN268201100003C, HHSN268201100004C and HHSN271201100004C). This work was also funded by 
NCI U19 CA148065-01. 
 
Acknowledgements: 
We thank all the individuals who took part in these studies and all the researchers, clinicians, technicians 
and administrative staff who have enabled this work to be carried out. The COGS study would not have 
been possible without the contributions of the following: Manjeet K. Bolla, Qin Wang (BCAC), Ali Amin Al 
Olama, Sara Benlloch (PRACTICAL), Georgia Chenevix-Trench, Antonis Antoniou, Lesley McGuffog, 
Fergus Couch and Ken Offit (CIMBA), Alison M. Dunning, Andrew Lee, and Ed Dicks, Craig Luccarini and 
the staff of the Centre for Genetic Epidemiology Laboratory, Javier Benitez, Anna Gonzalez-Neira and 
the staff of the CNIO genotyping unit, Daniel C. Tessier, Francois Bacot, Daniel Vincent, Sylvie LaBoissière 
and Frederic Robidoux and the staff of the McGill University and Génome Québec Innovation Centre, 
Stig E. Bojesen, Sune F. Nielsen, Borge G. Nordestgaard, and the staff of the Copenhagen DNA 
laboratory, and Julie M. Cunningham, Sharon A. Windebank, Christopher A. Hilker, Jeffrey Meyer and 
the staff of Mayo Clinic Genotyping Core Facility. ABCFS thank Maggie Angelakos, Judi Maskiell, Gillian 
Dite. ABCS thanks the Blood bank Sanquin, The Netherlands. ABCTB Investigators: Christine Clarke, 
Rosemary Balleine, Robert Baxter, Stephen Braye, Jane Carpenter, Jane Dahlstrom, John Forbes, Soon 
Lee, Debbie Marsh, Adrienne Morey, Nirmala Pathmanathan, Rodney Scott, Allan Spigelman, Nicholas 
Wilcken, Desmond Yip.  Samples are made available to researchers on a non-exclusive basis. The ACP 
study wishes to thank the participants in the Thai Breast Cancer study. Special Thanks also go to the Thai 
Ministry of Public Health (MOPH), doctors and nurses who helped with the data collection process. 
Finally, the study would like to thank Dr Prat Boonyawongviroj, the former Permanent Secretary of 
MOPH and Dr Pornthep Siriwanarungsan, the Department Director-General of Disease Control who have 
supported the study throughout. BBCS thanks Eileen Williams, Elaine Ryder-Mills, Kara Sargus. BCEES 
thanks Allyson Thomson, Christobel Saunders, Terry Slevin, BreastScreen Western Australia, Elizabeth 
Wylie, Rachel Lloyd. The BCINIS study would not have been possible without the contributions of Dr. K. 
Landsman, Dr. N. Gronich, Dr. A. Flugelman, Dr. W. Saliba, Dr. E. Liani, Dr. I. Cohen, Dr. S. Kalet, Dr. V. 
Friedman, Dr. O. Barnet of the NICCC in Haifa, and all the contributing family medicine, surgery, 
pathology and oncology teams in all medical institutes in Northern Israel. BIGGS thanks Niall McInerney, 
Gabrielle Colleran, Andrew Rowan, Angela Jones. The BREOGAN study would not have been possible 
without the contributions of the following: Manuela Gago-Dominguez, Jose Esteban Castelao, Angel 
Carracedo, Victor Muñoz Garzón, Alejandro Novo Domínguez, Maria Elena Martinez, Sara Miranda 
Ponte, Carmen Redondo Marey, Maite Peña Fernández, Manuel Enguix Castelo, Maria Torres, Manuel 
Calaza (BREOGAN), José Antúnez, Máximo Fraga and the staff of the Department of Pathology and 
Biobank of the University Hospital Complex of Santiago-CHUS, Instituto de Investigación Sanitaria de 
Santiago, IDIS, Xerencia de Xestion Integrada de Santiago-SERGAS; Joaquín González-Carreró and the 
staff of the Department of Pathology and Biobank of University Hospital Complex of Vigo, Instituto de 
Investigacion Biomedica Galicia Sur, SERGAS, Vigo, Spain. BSUCH thanks Peter Bugert, Medical Faculty 
Mannheim. The CAMA study would like to recognize CONACyT for the financial support provided for this 
work and all physicians responsible for the project in the different participating hospitals: Dr. Germán 
Castelazo (IMSS, Ciudad de México, DF), Dr. Sinhué Barroso Bravo (IMSS, Ciudad de México, DF), Dr. 
Fernando Mainero Ratchelous (IMSS, Ciudad de México, DF), Dr. Joaquín Zarco Méndez (ISSSTE, Ciudad 
de México, DF), Dr. Edelmiro Pérez Rodríguez (Hospital Universitario, Monterrey, Nuevo León), Dr. Jesús 
Pablo Esparza Cano (IMSS, Monterrey, Nuevo León), Dr. Heriberto Fabela (IMSS, Monterrey, Nuevo 
León), Dr. Fausto Hernández Morales (ISSSTE, Veracruz, Veracruz), Dr. Pedro Coronel Brizio (CECAN SS, 
Xalapa, Veracruz) and Dr. Vicente A. Saldaña Quiroz (IMSS, Veracruz, Veracruz). CBCS thanks study 
participants, co-investigators, collaborators and staff of the Canadian Breast Cancer Study, and project 
coordinators Agnes Lai and Celine Morissette. CCGP thanks Styliani Apostolaki, Anna Margiolaki, 
Georgios Nintos, Maria Perraki, Georgia Saloustrou, Georgia Sevastaki, Konstantinos Pompodakis. CGPS 
thanks staff and participants of the Copenhagen General Population Study. For the excellent technical 
assistance: Dorthe Uldall Andersen, Maria Birna Arnadottir, Anne Bank, Dorthe Kjeldgård Hansen. The 
 16 
Danish Cancer Biobank is acknowledged for providing infrastructure for the collection of blood samples 
for the cases. CNIO-BCS thanks Guillermo Pita, Charo Alonso, Nuria Álvarez, Pilar Zamora, Primitiva 
Menendez, the Human Genotyping-CEGEN Unit (CNIO). COLBCCC thanks all patients, the physicians 
Justo G. Olaya, Mauricio Tawil, Lilian Torregrosa, Elias Quintero, Sebastian Quintero, Claudia Ramírez, 
José J. Caicedo, and Jose F. Robledo, the researchers Diana Torres, Ignacio Briceno, Fabian Gil, Angela 
Umana, Angela Beltran and Viviana Ariza, and the technician Michael Gilbert for their contributions and 
commitment to this study. Investigators from the CPS-II cohort thank the participants and Study 
Management Group for their invaluable contributions to this research. They also acknowledge the 
contribution to this study from central cancer registries supported through the Centers for Disease 
Control and Prevention National Program of Cancer Registries, as well as cancer registries supported by 
the National Cancer Institute Surveillance Epidemiology and End Results program. The CTS Steering 
Committee includes Leslie Bernstein, Susan Neuhausen, James Lacey, Sophia Wang, Huiyan Ma, and  
Jessica Clague DeHart at the Beckman Research Institute of  City of Hope, Dennis Deapen, Rich Pinder, 
and Eunjung Lee at the University of Southern California, Pam Horn-Ross, Peggy Reynolds, Christina 
Clarke Dur and David Nelson at the Cancer Prevention Institute of California,  Hoda Anton-Culver, 
Argyrios Ziogas, and Hannah Park at the University of California Irvine, and Fred Schumacher at Case 
Western University. DIETCOMPLYF thanks the patients, nurses and clinical staff involved in the study. 
The DietCompLyf study was funded by the charity Against Breast Cancer (Registered Charity Number 
1121258) and the NCRN. We thank the participants and the investigators of EPIC (European Prospective 
Investigation into Cancer and Nutrition). ESTHER thanks Hartwig Ziegler, Sonja Wolf, Volker Hermann, 
Christa Stegmaier, Katja Butterbach. FHRISK thanks NIHR for funding. GC-HBOC thanks Stefanie Engert, 
Heide Hellebrand, Sandra Kröber and LIFE - Leipzig Research Centre for Civilization Diseases (Markus 
Loeffler, Joachim Thiery, Matthias Nüchter, Ronny Baber). The GENICA Network: Dr. Margarete Fischer-
Bosch-Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Germany [HB, Wing-Yee 
Lo], German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) [HB], Deutsche 
Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy - 
EXC 2180 - 390900677 [HB], Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, 
Johanniter Krankenhaus, Bonn, Germany [Yon-Dschun Ko, Christian Baisch], Institute of Pathology, 
University of Bonn, Germany [Hans-Peter Fischer], Molecular Genetics of Breast Cancer, Deutsches 
Krebsforschungszentrum (DKFZ), Heidelberg, Germany [Ute Hamann], Institute for Prevention and 
Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University 
Bochum (IPA), Bochum, Germany [Thomas Brüning, Beate Pesch, Sylvia Rabstein, Anne Lotz]; and 
Institute of Occupational Medicine and Maritime Medicine, University Medical Center Hamburg-
Eppendorf, Germany [Volker Harth]. GLACIER thanks Kelly Kohut, Patricia Gorman, Maria Troy. HABCS 
thanks Michael Bremer. HEBCS thanks Sofia Khan, Johanna Kiiski, Carl Blomqvist, Kristiina Aittomäki, 
Rainer Fagerholm, Kirsimari Aaltonen, Karl von Smitten, Irja Erkkilä. HKBCS thanks Hong Kong 
Sanatorium and Hospital, Dr Ellen Li Charitable Foundation, The Kerry Group Kuok Foundation, National 
Institute of Health 1R03CA130065 and the North California Cancer Center for support. HMBCS thanks 
Peter Hillemanns, Hans Christiansen and Johann H. Karstens. HUBCS thanks Shamil Gantsev. ICICLE 
thanks Kelly Kohut, Michele Caneppele, Maria Troy. KARMA and SASBAC thank the Swedish Medical 
Research Counsel. KBCP thanks Eija Myöhänen, Helena Kemiläinen. KConFab/AOCS wish to thank 
Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of 
the Family Cancer Clinics, and the Clinical Follow Up Study (which has received funding from the 
NHMRC, the National Breast Cancer Foundation, Cancer Australia, and the National Institute of Health 
(USA)) for their contributions to this resource, and the many families who contribute to kConFab. We 
thank all investigators of the KOHBRA (Korean Hereditary Breast Cancer) Study. LAABC thanks all the 
study participants and the entire data collection team, especially Annie Fung and June Yashiki. LMBC 
thanks Gilian Peuteman, Thomas Van Brussel, EvyVanderheyden and Kathleen Corthouts. MABCS thanks 
Milena Jakimovska (RCGEB “Georgi D. Efremov”), Emilija Lazarova (University Clinic of Radiotherapy and 
Oncology), Katerina Kubelka-Sabit, Mitko Karadjozov (Adzibadem-Sistina Hospital), Andrej Arsovski and 
Liljana Stojanovska (Re-Medika Hospital) for their contributions and commitment to this study. MARIE 
thanks Petra Seibold, Dieter Flesch-Janys, Judith Heinz, Nadia Obi, Alina Vrieling, Sabine Behrens, Ursula 
Eilber, Muhabbet Celik, Til Olchers and Stefan Nickels. MBCSG (Milan Breast Cancer Study Group): 
Paolo Radice, Paolo Peterlongo, Siranoush Manoukian, Bernard Peissel, Roberto Villa, Cristina 
 17 
Zanzottera, Bernardo Bonanni, Irene Feroce, and the personnel of the Cogentech Cancer Genetic Test 
Laboratory. The MCCS was made possible by the contribution of many people, including the original 
investigators, the teams that recruited the participants and continue working on follow-up, and the 
many thousands of Melbourne residents who continue to participate in the study. We thank the 
coordinators, the research staff and especially the MMHS participants for their continued collaboration 
on research studies in breast cancer. MSKCC thanks Marina Corines, Lauren Jacobs. MTLGEBCS would 
like to thank Martine Tranchant (CHU de Québec – Université Laval Research Center), Marie-France 
Valois, Annie Turgeon and Lea Heguy (McGill University Health Center, Royal Victoria Hospital; McGill 
University) for DNA extraction, sample management and skilful technical assistance. J.S. is Chair holder 
of the Canada Research Chair in Oncogenetics. MYBRCA thanks study participants and research staff 
(particularly Patsy Ng, Nurhidayu Hassan, Yoon Sook-Yee, Daphne Lee, Lee Sheau Yee, Phuah Sze Yee 
and Norhashimah Hassan) for their contributions and commitment to this study. The following are NBCS 
Collaborators: Kristine K. Sahlberg (PhD), Lars Ottestad (MD), Rolf Kåresen (Prof. Em.) Dr. Ellen 
Schlichting (MD), Marit Muri Holmen (MD), Toril Sauer (MD), Vilde Haakensen (MD), Olav Engebråten 
(MD), Bjørn Naume (MD), Alexander Fosså (MD), Cecile E. Kiserud (MD), Kristin V. Reinertsen (MD), 
Åslaug Helland (MD), Margit Riis (MD), Jürgen Geisler (MD), OSBREAC and Grethe I. Grenaker Alnæs 
(MSc). NBHS and SBCGS thank study participants and research staff for their contributions and 
commitment to the studies. For NHS and NHS2 the study protocol was approved by the institutional 
review boards of the Brigham and Women’s Hospital and Harvard T.H. Chan School of Public Health, and 
those of participating registries as required. We would like to thank the participants and staff of the NHS 
and NHS2 for their valuable contributions as well as the following state cancer registries for their help: 
AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, 
OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and 
interpretation of these data. OBCS thanks Arja Jukkola-Vuorinen, Mervi Grip, Saila Kauppila, Meeri 
Otsukka, Leena Keskitalo and Kari Mononen for their contributions to this study. OFBCR thanks Teresa 
Selander, Nayana Weerasooriya. ORIGO thanks E. Krol-Warmerdam, and J. Blom for patient accrual, 
administering questionnaires, and managing clinical information. The LUMC survival data were retrieved 
from the Leiden hospital-based cancer registry system (ONCDOC) with the help of Dr. J. Molenaar. PBCS 
thanks Louise Brinton, Mark Sherman, Neonila Szeszenia-Dabrowska, Beata Peplonska, Witold Zatonski, 
Pei Chao, Michael Stagner. The ethical approval for the POSH study is MREC /00/6/69, UKCRN ID: 1137. 
We thank staff in the Experimental Cancer Medicine Centre (ECMC) supported Faculty of Medicine 
Tissue Bank and the Faculty of Medicine DNA Banking resource. PREFACE thanks Sonja Oeser and Silke 
Landrith. PROCAS thanks NIHR for funding. RBCS thanks Jannet Blom, Saskia Pelders, Annette 
Heemskerk and the Erasmus MC Family Cancer Clinic. SBCS thanks Sue Higham, Helen Cramp, Dan 
Connley, Ian Brock, Sabapathy Balasubramanian and Malcolm W.R. Reed. We thank the SEARCH and 
EPIC teams. SGBCC thanks the participants and research coordinator Ms Tan Siew Li. SKKDKFZS thanks 
all study participants, clinicians, family doctors, researchers and technicians for their contributions and 
commitment to this study. We thank the SUCCESS Study teams in Munich, Duessldorf, Erlangen and 
Ulm. SZBCS thanks Ewa Putresza. UCIBCS thanks Irene Masunaka. UKBGS thanks Breast Cancer Now and 
the Institute of Cancer Research for support and funding of the Breakthrough Generations Study, and 
the study participants, study staff, and the doctors, nurses and other health care providers and health 
information sources who have contributed to the study. We acknowledge NHS funding to the Royal 
Marsden/ICR NIHR Biomedical Research Centre. We acknowledge funding to the Manchester NIHR 
Biomedical Research Centre (IS-BRC-1215-20007). The authors thank the WHI investigators and staff for 
their dedication and the study participants for making the program possible. 
 
BEACON 
The MD Anderson controls for BEACON were drawn from dbGaP (study accession: phs000187.v1.p1). 
Genotyping of these controls were done through the University of Texas MD Anderson Cancer Center 
(UTMDACC) and the Johns Hopkins University Center for Inherited Disease Research (CIDR). We 
acknowledge the principal investigators of this study: Christopher Amos, Qingyi Wei, and Jeffrey E Lee. 
Controls from the Genome-Wide Association Study of Parkinson Disease were obtained from dbGaP 
(study accession: phs000196.v2.p1). This work, in part, used data from the National Institute of 
 18 
Neurological Disorders and Stroke (NINDS) dbGaP database from the CIDR: NeuroGenetics Research 
Consortium Parkinson’s disease study. We acknowledge the principal investigators and coinvestigators 
of this study: Haydeh Payami, John Nutt, Cyrus Zabetian, Stewart Factor, Eric Molho, and Donald 
Higgins. Controls from the Chronic Renal Insufficiency Cohort (CRIC) were drawn from dbGaP (study 
accession: phs000524.v1.p1). The CRIC study was done by the CRIC investigators and supported by the 
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Data and samples from CRIC 
reported here were supplied by NIDDK Central Repositories. This report was not prepared in 
collaboration with investigators of the CRIC study and does not necessarily reflect the opinions or views 
of the CRIC study, the NIDDK Central Repositories, or the NIDDK. We acknowledge the principal 
investigators and the project officer of this study: Harold I Feldman, Raymond R Townsend, Lawrence J 
Appel, Mahboob Rahman, Akinlolu Ojo, James P Lash, Jiang He, Alan S Go, and John W Kusek. This work 
was supported by funding from the US National Cancer Institute at the National Institutes of Health 
(grant number R01CA136725 awarded to T.L.V and D.C.W), grants (R01 CA57947-03) from the National 
Cancer Institute and the Swedish Cancer Society (4559-B01-01XAA, 4758-B02-01XAB), US NIH grants 
(R01DK63616, R01CA59636), the California Tobacco Related Research Program (3RT-0122 and 10RT-
0251), grant number 5 RO1 CA 001833-02 from the National Cancer Institute, and Program Grants (nos. 




The authors thank the many individuals who participated in this study and the numerous institutions 
and their staff who supported recruitment. 
 
The iCOGS and OncoArray endometrial cancer analysis were supported by NHMRC project grants 
[ID#1031333 & ID#1109286] Funding for the iCOGS infrastructure came from: the European 
Community's Seventh Framework Programme under grant agreement no 223175 [HEALTH-F2-2009-
223175] [COGS], Cancer Research UK [C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, 
C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565], the National Institutes of Health 
[CA128978] and Post-Cancer GWAS initiative [1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - 
the GAME-ON initiative], the Department of Defence [W81XWH-10-1-0341], the Canadian Institutes of 
Health Research [CIHR] for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the 
Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. OncoArray 
genotyping of ECAC cases was performed with the generous assistance of the Ovarian Cancer 
Association Consortium (OCAC). We particularly thank the efforts of Cathy Phelan. The OCAC OncoArray 
genotyping project was funded through grants from the US National Institutes of Health 
(CA1X01HG007491-01, U19-CA148112, R01-CA149429 and R01-CA058598); Canadian Institutes of 
Health Research (MOP-86727); and the Ovarian Cancer Research Fund. CIDR genotyping for the 
Oncoarray was conducted under contract 268201200008I. OncoArray genotyping of the BCAC controls 
was funded by Genome Canada Grant GPH-129344, NIH Grant U19 CA148065, and Cancer UK Grant 
C1287/A16563. 
 
Stage 1 and stage 2 case genotyping was supported by the NHMRC [ID#552402, ID#1031333]. Control 
data were generated by the Wellcome Trust Case Control Consortium (WTCCC), and a full list of the 
investigators who contributed to the generation of the data is available from the WTCCC website. We 
acknowledge use of DNA from the British 1958 Birth Cohort collection, funded by the Medical Research 
Council grant G0000934 and the Wellcome Trust grant 068545/Z/02 - funding for this project was 
provided by the Wellcome Trust under award 085475. NSECG was supported by the EU FP7 CHIBCHA 
grant, Wellcome Trust Centre for Human Genetics Core Grant 090532/Z/09Z, and CORGI was funded by 
Cancer Research UK. We thank Nick Martin, Dale Nyholt and Anjali Henders for access to GWAS data 
from QIMR Controls. Recruitment of the QIMR controls was supported by the NHMRC. The University of 
Newcastle, the Gladys M Brawn Senior Research Fellowship scheme, The Vincent Fairfax Family 
 19 
Foundation, the Hunter Medical Research Institute and the Hunter Area Pathology Service all 
contributed towards the costs of establishing the Hunter Community Study. The WHI program is funded 
by the National Heart, Lung, and Blood Institute, the US National Institutes of Health and the US 
Department of Health and Human Services (HHSN268201100046C, HHSN268201100001C, 
HHSN268201100002C, HHSN268201100003C, HHSN268201100004C and HHSN271201100004C). This 
work was also funded by NCI U19 CA148065-01. This research has been conducted using the UK Biobank 
Resource under applications 5122 and 9797. 
 
ANECS recruitment was supported by project grants from the NHMRC [ID#339435], The Cancer Council 
Queensland [ID#4196615] and Cancer Council Tasmania [ID#403031 and ID#457636]. SEARCH 
recruitment was funded by a programme grant from Cancer Research UK [C490/A10124]. The Bavarian 
Endometrial Cancer Study (BECS) was partly funded by the ELAN fund of the University of Erlangen. The 
Hannover-Jena Endometrial Cancer Study was partly supported by the Rudolf Bartling Foundation. The 
Leuven Endometrium Study (LES) was supported by the Verelst Foundation for endometrial cancer. The 
Mayo Endometrial Cancer Study (MECS) and Mayo controls (MAY) were supported by grants from the 
National Cancer Institute of United States Public Health Service [R01 CA122443, P30 CA15083, P50 
CA136393, and GAME-ON the NCI Cancer Post-GWAS Initiative U19 CA148112], the Fred C and 
Katherine B Andersen Foundation, the Mayo Foundation, and the Ovarian Cancer Research Fund with 
support of the Smith family, in memory of Kathryn Sladek Smith. MoMaTEC received financial support 
from a Helse Vest Grant, the University of Bergen, Melzer Foundation, The Norwegian Cancer Society 
(Harald Andersens legat), The Research Council of Norway and Haukeland University Hospital. The 
Newcastle Endometrial Cancer Study (NECS) acknowledges contributions from the University of 
Newcastle, The NBN Children’s Cancer Research Group, Ms Jennie Thomas and the Hunter Medical 
Research Institute. RENDOCAS was supported through the regional agreement on medical training and 
clinical research (ALF) between Stockholm County Council and Karolinska Institutet [numbers: 
20110222, 20110483, 20110141 and DF 07015], The Swedish Labor Market Insurance [number 100069] 
and The Swedish Cancer Society [number 11 0439]. The Cancer Hormone Replacement Epidemiology in 
Sweden Study (CAHRES, formerly called The Singapore and Swedish Breast/Endometrial Cancer Study; 
SASBAC) was supported by funding from the Agency for Science, Technology and Research of Singapore 
(A*STAR), the US National Institutes of Health and the Susan G. Komen Breast Cancer Foundation.  
 
The Nurses’ Health Study (NHS) is supported by the NCI, NIH Grants Number UM1 CA186107, P01 
CA087969, R01 CA49449, 1R01 CA134958, and 2R01 CA082838. The authors thank the participants and 
staff of the Nurses’ Health Study for their valuable contributions as well as the following state cancer 
registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, 
NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for 
analyses and interpretation of these data. The authors also thank Channing Division of Network 
Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School. Finally, 
the authors also acknowledge Pati Soule and Hardeep Ranu for their laboratory assistance. The 
Connecticut Endometrial Cancer Study was supported by NCI, NIH Grant Number RO1CA98346. The Fred 
Hutchinson Cancer Research Center (FHCRC) is supported by NCI, NIH Grant Number NIH RO1 
CA105212, RO1 CA 87538, RO1 CA75977, RO3 CA80636, NO1 HD23166, R35 CA39779, KO5 CA92002 and 
funds from the Fred Hutchinson Cancer Research Center. The Multiethnic Cohort Study (MEC) is 
supported by the NCI, NHI Grants Number CA54281, CA128008 and 2R01 CA082838. The California 
Teachers Study (CTS) is supported by NCI, NIH Grant Number 2R01 CA082838, R01 CA91019 and R01 
CA77398, and contract 97-10500 from the California Breast Cancer Research Fund. The Polish 
Endometrial Cancer Study (PECS) is supported by the Intramural Research Program of the NCI. The 
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) is supported by the Extramural 
and the Intramural Research Programs of the NCI. 
 
 
GECCO, CORECT, CCFR 
Funding: 
 20 
Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO): National Cancer Institute, 
National Institutes of Health, U.S. Department of Health and Human Services (U01 CA137088, U01 
CA164930, R01201407). Genotyping/Sequencing services were provided by the Center for Inherited 
Disease Research (CIDR) (X01-HG008596 and X-01-HG007585). CIDR is fully funded through a federal 
contract from the National Institutes of Health to The Johns Hopkins University, contract number 
HHSN268201200008I. This research was funded in part through the NIH/NCI Cancer Center Support 
Grant P30 CA015704. ASTERISK: a Hospital Clinical Research Program (PHRC-BRD09/C) from the 
University Hospital Center of Nantes (CHU de Nantes) and supported by the Regional Council of Pays de 
la Loire, the Groupement des Entreprises Françaises dans la Lutte contre le Cancer (GEFLUC), the 
Association Anne de Bretagne Génétique and the Ligue Régionale Contre le Cancer (LRCC). COLO2&3: 
National Institutes of Health (R01 CA60987). The Colon Cancer Family Registry (CFR) Illumina GWAS was 
supported by funding from the National Cancer Institute, National Institutes of Health (grant numbers 
U01 CA122839, R01 CA143247 to G Casey). The Colon CFR/CORECT Affymetrix Axiom GWAS and 
OncoArray GWAS were supported by funding from National Cancer Institute, National Institutes of 
Health (grant number U19 CA148107 to S Gruber). The Colon CFR participant recruitment and collection 
of data and biospecimens used in this study were supported by the National Cancer Institute, National 
Institutes of Health (grant number U01 CA167551) and through cooperative agreements with the 
following Colon CFR centers: Australasian Colorectal Cancer Family Registry (NCI/NIH grant numbers 
U01 CA074778 and U01/U24 CA097735), USC Consortium Colorectal Cancer Family Registry (NCI/NIH 
grant numbers U01/U24 CA074799), Mayo Clinic Cooperative Family Registry for Colon Cancer Studies 
(NCI/NIH grant number U01/U24 CA074800), Ontario Familial Colorectal Cancer Registry (NCI/NIH grant 
number U01/U24 CA074783 to S Gallinger), Seattle Colorectal Cancer Family Registry (NCI/NIH grant 
number U01/U24 CA074794), and University of Hawaii Colorectal Cancer Family Registry (NCI/NIH grant 
number U01/U24 CA074806), Additional support for case ascertainment was provided from the 
Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute to Fred 
Hutchinson Cancer Research Center (Control Nos. N01-CN-67009 and N01-PC-35142, and Contract No. 
HHSN2612013000121), the Hawai‘i Department of Health (Control Nos. N01-PC- 67001 and N01-PC-
35137, and Contract No. HHSN26120100037C, and the California Department of Public Health (contracts 
HHSN261201000035C awarded to the University of Southern California, and the following state cancer 
registries: AZ, CO, MN, NC, NH, and by the Victoria Cancer Registry and Ontario Cancer Registry. 
Colorectal Cancer Transdisciplinary (CORECT) Study: The CORECT Study was supported by the National 
Cancer Institute, National Institutes of Health (NCI/NIH), U.S. Department of Health and Human Services 
(grant numbers U19 CA148107, R01 CA81488, P30 CA014089, R01 CA197350,; P01 CA196569; R01 
CA201407) and National Institutes of Environmental Health Sciences, National Institutes of Health (grant 
number T32 ES013678). CPS-II: The American Cancer Society funds the creation, maintenance, and 
updating of the Cancer Prevention Study-II (CPS-II) cohort. This study was conducted with Institutional 
Review Board approval. DACHS: This work was supported by the German Research Council (BR 1704/6-
1, BR 1704/3, BR 1704/6-4, CH 117/1-1, HO 5117/2-1, HE 5998/2-1, KL 2354/3-1, RO 2270/8-1 and BR 
1704/17-1), the Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT), 
Germany, and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 
01ER0815, 01ER1505A and 01ER1505B). DALS: National Institutes of Health (R01 CA48998 to M. L. 
Slattery). Harvard cohorts (HPFS, NHS, PHS): HPFS is supported by the National Institutes of Health (P01 
CA055075, UM1 CA167552, U01 CA167552, R01 CA137178, R01 CA151993, R35 CA197735, K07 
CA190673, and P50 CA127003), NHS by the National Institutes of Health (R01 CA137178, P01 CA087969, 
UM1 CA186107, R01 CA151993, R35 CA197735, K07 CA190673, and P50 CA127003) and PHS by the 
National Institutes of Health (R01 CA042182). Kentucky: This work was supported by the following grant 
support: Clinical Investigator Award from Damon Runyon Cancer Research Foundation (CI-8); NCI 
R01CA136726. MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The 
 21 
MCCS was further supported by Australian NHMRC grants 509348, 209057, 251553 and 504711 and by 
infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through 
the Victorian Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW), including 
the National Death Index and the Australian Cancer Database. MEC: National Institutes of Health (R37 
CA54281, P01 CA033619, and R01 CA063464). MECC: This work was supported by the National 
Institutes of Health, U.S. Department of Health and Human Services (R01 CA81488 to SBG and GR). 
NFCCR: This work was supported by an Interdisciplinary Health Research Team award from the Canadian 
Institutes of Health Research (CRT 43821); the National Cancer Institute of Canada grants (18223 and 
18226). The authors wish to acknowledge the contribution of Alexandre Belisle and the genotyping team 
of the McGill University and Génome Québec Innovation Centre, Montréal, Canada, for genotyping the 
Sequenom panel in the NFCCR samples. Funding was provided to Michael O. Woods by the Canadian 
Cancer Society Research Institute. PMH-SCCFR: National Cancer Institute, National Institutes of Health 
(grant numbers U01 CA167551, U01 CA074794 to J Potter and R01 CA076366 to P.A. Newcomb). VITAL: 
National Institutes of Health (K05 CA154337). WHI: The WHI program is funded by the National Heart, 
Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services 
through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, 
HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. 
 
Acknowledgements: 
ASTERISK: We are very grateful to Dr. Bruno Buecher without whom this project would not have existed. 
We also thank all those who agreed to participate in this study, including the patients and the healthy 
control persons, as well as all the physicians, technicians and students. CPS-II: The authors thank the 
CPS-II participants and Study Management Group for their invaluable contributions to this research. The 
authors would also like to acknowledge the contribution to this study from central cancer registries 
supported through the Centers for Disease Control and Prevention National Program of Cancer 
Registries, and cancer registries supported by the National Cancer Institute Surveillance Epidemiology 
and End Results program. DACHS: We thank all participants and cooperating clinicians, and Ute Handte-
Daub, Utz Benscheid, Muhabbet Celik and Ursula Eilber for excellent technical assistance. Harvard 
cohorts (HPFS, NHS, PHS): The study protocol was approved by the institutional review boards of the 
Brigham and Women’s Hospital and Harvard T.H. Chan School of Public Health, and those of 
participating registries as required. We would like to thank the participants and staff of the HPFS, NHS 
and PHS for their valuable contributions as well as the following state cancer registries for their help: AL, 
AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, 
PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of 
these data. Kentucky: We would like to acknowledge the staff at the Kentucky Cancer Registry. OFCCR: 
Additional funding toward genetic analyses of OFCCR includes the Ontario Research Fund, the Canadian 
Institutes of Health Research, and the Ontario Institute for Cancer Research, through generous support 
from the Ontario Ministry of Research and Innovation. PLCO: The authors thank the PLCO Cancer 
Screening Trial screening center investigators and the staff from Information Management Services Inc 
and Westat Inc. Most importantly, we thank the study participants for their contributions that made this 
study possible. WHI: The authors thank the WHI investigators and staff for their dedication, and the 





The melanoma meta-analysis makes use of data from two dbGap datasets (accession phs000187.v1.p1 
and phs000519.v1.p1 ) GenoMEL: The GenoMEL study (http://www.genomel.org/) was funded by the 
 22 
European Commission under the 6th Framework Programme (contract no. LSHC-CT-2006-018702), by 
Cancer Research UK Programme Awards (C588/A4994 , C588/A10589 and C588/A19167), by a Cancer 
Research UK Project Grant (C8216/A6129) and by a grant from the US National Institutes of Health (NIH; 
CA83115). This research was also supported by the intramural Research Program of the NIH, National 
Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics. This study makes use of data 
generated by the Wellcome Trust Case Control Consortium (http://www.wtccc.org.uk/). A full list of the 
investigators who contributed to the generation of the data is available from their website (see URLs). 
Funding for the project was provided by the Wellcome Trust under award 076113. Genotyping for the 
CIDRUK samples were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded 
through a federal contract from the National Institutes of Health to The Johns Hopkins University, 
contract number HHSN268201200008I. 
 
Funding specific to particular centers is given below: 
Stockholm: Swedish Cancer Society, Karolinska Institutet Research Funds, Radiumhemmet Research 
Funds, Stockholm County Council Research Funding (ALF). Lund: Funding to be acknowledged; Swedish 
Cancer Society, Gunnar Nilsson Foundation, and European Research Council Advanced Grant (ERC-2011–
294576). Genoa: Italian Ministry of Education, University and Research PRIN 2008, IMI and Mara Naum 
foundation. Italian association for cancer research (AIRC) IG 2014 (15460) to PG; IRCCS AOU San 
Martino-IST Istituto Nazionale per la Ricerca sul Cancro, 5% per la ricerca corrente, to PG and GBS. 
Leiden: Grant provided by European Biobanking and Biomolecular Resources Research Infrastructure 
(BBMRI) −Netherlands hub (CO18). Spain: The research at the Melanoma Unit in Barcelona is or was 
partially funded by Grants from Fondo de Investigaciones Sanitarias P.I. 09/01393 & 12/00840, Spain; by 
the CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain; by the AGAUR 2009 SGR 
1337 and AGAUR 2014_SGR_603 of the Catalan Government, Spain; by a grant from “Fundació La 
Marató de TV3, 201331-30”, Catalonia, Spain; by the European Commission under the 6th Framework 
Programme, Contract no: LSHC-CT-2006-018702 (GenoMEL) and by the National Cancer Institute (NCI) 
of the US National Institute of Health (NIH) (CA83115). Norway: Grants from the Comprehensive Cancer 
Center, Oslo University Hospital (SE0728) and the Norwegian Cancer Society (71512-PR-2006-0356). 
AMFS: The AMFS was supported by the National Health and Medical Research Council of Australia 
(NHMRC) (project grants 566946, 107359, 211172 and program grant number 402761 to GJM and RFK); 
the Cancer Council New South Wales (project grant 77/00, 06/10), the Cancer Council Victoria and the 
Cancer Council Queensland (project grant 371); and the US National Institutes of Health (NIH RO1 grant 
CA-83115-01A2 and 2R01CA083115-11A1 to the international Melanoma Genetics Consortium - 
GenoMEL). Anne E. Cust is supported by fellowships from the Cancer Institute NSW and the NHMRC. We 
gratefully acknowledge all of the participants, and the work and dedication of the research coordinators, 
interviewers, examiners and data management staff. WAMHS: The WAMHS gratefully acknowledges all 
study participants for their time and contributions, and the Western Australian DNA Bank and the Ark at 
The University of Western Australia for biospecimen and bioinformatics related support. The Western 
Australian Cancer Registry, the WAMHS study team and the WAMHS Management Committee are also 
gratefully acknowledged for their assistance, as well as the Scott Kirkbride Melanoma Research Centre 
for funding received to establish the WAMHS resource and related salaries and PhD stipends. The 
Cancer Council Western Australia is also acknowledged for current salary support for Sarah Ward 
(Capacity Building and Collaboration grant). Genotyping services were provided by the Center for 
Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National 
Institutes of Health to The Johns Hopkins University, contract number HHSN268201200008I. Q-MEGA 
cases and QTWINs controls (used in Q-MEGA_610k set): Brisbane: Q-MEGA and QTWIN thanks A. 
Baxter, M. de Nooyer, I. Gardner, D. Statham, B. Haddon, M.J. Wright, J. Palmer, J. Symmons, B. 
Castellano, L. Bardsley, S. Smith, D. Smyth, L. Wallace, M.J. Campbell, A. Caracella, M. Kvaskoff, O. 
 23 
Zheng, B. Chapman and H. Beeby for their input in project management, sample processing and 
database development. We are grateful to the many research assistants and interviewers for assistance 
with the studies contributing to the QMEGA and QTWIN collections. The Q-MEGA/QTWIN study was 
supported by the Melanoma Research Alliance, the NIH NCI (CA88363, CA83115, CA122838, CA87969, 
CA055075, CA100264, CA133996 and CA49449), the National Health and Medical Research Council of 
Australia (NHMRC) (200071, 241944, 339462, 380385, 389927,389875, 389891, 389892,389938, 
443036, 442915, 442981, 496610, 496675, 496739, 552485, 552498), the Cancer Councils New South 
Wales, Victoria and Queensland, the Cancer Institute New South Wales, the Cooperative Research 
Centre for Discovery of Genes for Common Human Diseases (CRC), Cerylid Biosciences (Melbourne), the 
Australian Cancer Research Foundation, The Wellcome Trust (WT084766/Z/08/Z) and donations from 
Neville and Shirley Hawkins. Stuart MacGregor acknowledges fellowship support from the Australian 
National Health and Medical Research Council and from an Australian Research Council Future 
Fellowship. Endometriosis: Contributors to the Endometriosis collection: Anjali K. Henders, S.H. 
Kennedy, S. Macgregor, N.G. Martin, S. Missmer, G.W. Montgomery, D.R. Nyholt, J.N. Painter, S.A. 
Treloar, L. Wallace, K.T. Zondervan. Acknowledgements: We acknowledge all the participants in the 
QIMR and endometriosis studies. We thank Anjali Henders, Leanne Wallace, and Lisa Bardsley for 
project management, sample processing and database development. We thank Endometriosis 
Associations for supporting study recruitment and S. Nicolaides and the Queensland Medical Laboratory 
for assistance with blood collection including pro bono collection and delivery of blood samples. 
Funding: This work was supported by the Cooperative Research Centre (CRC) for Discovery of Genes for 
Common. Human Diseases, Cerylid Biosciences (Melbourne), The Wellcome Trust and donations from 
Neville and Shirley Hawkins. Endometriosis sample genotyping was funded by a grant from the 
Wellcome Trust (WT084766/Z/08/Z) and NHMRC (496610). G.W.M. is supported by the NHMRC 
Fellowships scheme. D.R.N. was supported by the NHMRC Fellowship (613674) and Australian Research 
Council (ARC) Future Fellowship (FT0991022) schemes. Study of Digestive Health: Controls for use with 
the Q-MEGA_omni dataset were derived from the Study of Digestive Health group (SDH). The SDH was 
supported by grant number 5 RO1 CA 001833-02 from the National Cancer Institute. Its contents are 
solely the responsibility of the authors and do not necessarily represent the official views of the National 
Cancer Institute. We gratefully acknowledge the cooperation of the following institutions: Sullivan and 
Nicolaides Pathology (Brisbane); Queensland Medical Laboratory (Brisbane); Queensland Health 
Pathology Services (Brisbane); Institute of Medical and Veterinary Science (Adelaide); SouthPath 
(Adelaide). We also acknowledge the contribution of the study nurses and research assistants and would 
like to thank all of the people who participated in the study. DCW was supported by an NHMRC 
Research Fellowship (APP1058522). Australian & New Zealand Registry of Advanced Glaucoma 
(ANZRAG): Support for recruitment of ANZRAG was provided by the Royal Australian and New Zealand 
College of Ophthalmology (RANZCO) Eye Foundation. Genotyping was funded by the National Health 
and Medical Research Council of Australia (#535074 and #1023911). This work was also supported by 
funding from the BrightFocus Foundation and a Ramaciotti Establishment Grant. The authors 
acknowledge the support of Ms. Bronwyn Usher-Ridge in patient recruitment and data collection, and 
Dr Patrick Danoy and Dr Johanna Hadler for genotyping. Inflammatory Bowel Disease (IBD): The authors 
express their thanks to Sullivan and Nicolaides Pathology, Queensland Medical Laboratories and the 
Queensland Health Pathology Service for identifying participants for this study. They are also grateful to 
Peter Schultz, Lauren Aoude, Loralie Parsonson, Stephen Walsh, Mitchell Stark, John Cardinal and 
Herlina Handoko for technical support. This research was supported by grant number CA 001833-03 
from the United States National Cancer Institute. Its contents are solely the responsibility of the authors 
and do not necessarily represent the official views of the National Cancer Institute. PMW and DCW are 
Senior Research Fellows of the National Health and Medical Research Council of Australia. NP is 
supported by a PhD scholarship from the National Health and Medical Research Council of Australia. The 
 24 
funding bodies played no role in the design or conduct of the study, the collection, management, 
analysis, or interpretation of the data, or the preparation, review or approval of the manuscript. M.D. 
Anderson: Funding was provided by NCI grant P50CA093459, as well as by philanthropic contributions 
to the University of Texas MD Anderson Cancer Center Moon Shots Program, the Miriam and Jim Mulva 
Melanoma Research Fund and the Marit Peterson Fund for Melanoma Research. The authors thank the 
John Hopkins University Center for Inherited Disease Research for conducting high-throughput 
genotyping and University of Washington for the performance of quality control of the high-density SNP 
data. MELARISK, Paris, France: Grants from Institut National du Cancer (INCa-PL016 and INCa_5982) to 
F. Demenais, Ligue Nationale Contre Le Cancer (PRE 09/FD to F. Demenais and doctoral fellowship to M. 
Brossard), Fondation pour la Recherche Medicale (FDT20130928343), Programme Hospitalier de 
Recherche Clinique (AOM-07-195) to M.-F. Avril and F. Demenais. Ministère de l’Enseignement 
Supérieur et de la Recherche and Institut National du Cancer (INCa) to M. Lathrop. The authors thank 
the Epidemiological Study on the Genetics and Environment of Asthma (EGEA) cooperative group for 
giving access to data of the EGEA study (https://egeanet.vjf.inserm.fr). We acknowledge that the 
biological specimens of the French MELARISK study were obtained from the Institut Gustave Roussy and 
Fondation Jean Dausset–CEPH Biobanks. Essen-Heidelberg: The study was supported by a grant from 
Deutsche Forshungsgemeinschaft (GZ: SCHA 422/11-1) Harvard: Funding was provided by NIH grant 
R03CA167741. Cambridge: SEARCH/MAPLES We would like to thank Don Conroy, Craig Luccarini and 
Rebecca Mayes for their technical assistance. Funding: A.M. Dunning received funding from Cancer 
Research UK (Grant Numbers, C8197/A10123, C8197/A10865) and K.A. Pooley from Cancer Research UK 
(Grant Number C1287/A9540) and The Isaac Newton Trust. The Cambridge melanoma studies were 
supported by Cancer Research UK grants C490/A10124 (SEARCH) and C1287/A10118 (MAPLES). Athens 
case control study: The present work was funded by Aristeia Program. This Program is co-funded by the 
European Social Fund and National Resources (Project code:1094). The funders had no role in study 
design, data collection and analysis, decision to publish, or preparation of the manuscript. Breakthrough 
Generations Study: The Breakthrough Generations Study thank Breakthrough Breast Cancer and the 
Institute of Cancer Research (ICR) for support and funding of the Breakthrough Generations Study, and 
the Study participants, Study staff, and the doctors, nurses and other health care staff and data 
providers who have contributed to the Study. The ICR acknowledge NHS funding to the NIHR Biomedical 
Research Centre. 
 
SM is supported by an Australian National Health and Medical Research Council Fellowship 
 
GICC 
Work at University of California, San Francisco was supported by the National Institutes of Health (grant 
numbers  R01CA52689, P50CA097257, R01CA126831, R01CA139020, R25CA112355, and 
1R01CA207360), as well as the loglio Collective, the Stanley D. Lewis and Virginia S. Lewis Endowed Chair 
in Brain Tumor Research, the Robert Magnin Newman Endowed Chair in Neuro-oncology, and by 
donations from families and friends of John Berardi, Helen Glaser, Elvera Olsen, Raymond E. Cooper, and 
William Martinusen. The collection of cancer incidence data used in this study was supported by the 
California Department of Public Health pursuant to California Health and Safety Code Section 103885; 
Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries, under 
cooperative agreement 5NU58DP006344; the National Cancer Institute’s Surveillance, Epidemiology and 
End Results Program under contract HHSN261201800032I awarded to the University of California, San 
Francisco, contract HHSN261201800015I awarded to the University of Southern California, and contract 
HHSN261201800009I awarded to the Public Health Institute, Cancer Registry of Greater California.  The 
ideas and opinions expressed herein are those of the author(s) and do not necessarily reflect the 
opinions of the State of California, Department of Public Health, the National Cancer Institute, and the 
 25 
Centers for Disease Control and Prevention or their Contractors and Subcontractors. This publication 
was supported by the National Center for Research Resources and the National Center for Advancing 
Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 RR024131. 
Its contents are solely the responsibility of the authors and do not necessarily represent the official 
views of the NIH. The authors wish to acknowledge study participants, the clinicians and research staff 
at the participating medical centers, the UCSF Cancer Registry for providing vital status and other data, 
the UCSF Neurosurgery Tissue Bank for histo-pathology services and providing human biospecimens, 
and the UCSF Helen Diller Family Comprehensive Cancer Center Genome Analysis Core which is 
supported by a National Cancer Institute Cancer Center Support Grant (5P30CA082103). JKW was 
supported by the National Institutes of Health with grants R01CA207360, and P50CA097257 and by the 




NIH/NCI U19CA203654 and Cancer Prevention and Research Institute of Texas RR170048. 
TRICL (U19 CA148127) and INTEGRAL (U19 CA203654). 
 
InterLymph 
Support for individual studies:  
ATBC – The ATBC Study is supported by the Intramural Research Program of the U.S. National Cancer 
Institute, National Institutes of Health, and by U.S. Public Health Service contract HHSN261201500005C 
from the National Cancer Institute, Department of Health and Human Services. BC – Canadian Institutes 
for Health Research (CIHR); Canadian Cancer Society; Michael Smith Foundation for Health Research. 
CPS-II - The Cancer Prevention Study-II (CPS-II) Nutrition Cohort is supported by the American Cancer 
Society. Genotyping for all CPS-II samples were supported by the Intramural Research Program of the 
National Institutes of Health, NCI, Division of Cancer Epidemiology and Genetics. The authors would also 
like to acknowledge the contribution to this study from central cancer registries supported through the 
Centers for Disease Control and Prevention National Program of Cancer Registries, and cancer registries 
supported by the National Cancer Institute Surveillance Epidemiology and End Results program. ELCCS - 
Leukaemia & Lymphoma Research. ENGELA – Association pour la Recherche contre le Cancer (ARC), 
Institut National du Cancer (INCa), Fondation de France, Fondation contre la Leucémie, Agence nationale 
de sécurité sanitaire de l’alimentation, de l’environnement et du travail (ANSES). EPIC – Coordinated 
Action (Contract #006438, SP23-CT-2005-006438); HuGeF (Human Genetics Foundation), Torino, Italy; 
Cancer Research UK. EpiLymph – European Commission (grant references QLK4-CT-2000-00422 and 
FOOD-CT-2006-023103); the Spanish Ministry of Health (grant references CIBERESP, PI11/01810, 
PI14/01219, RCESP C03/09, RTICESP C03/10 and RTIC RD06/0020/0095), the Marató de TV3 Foundation 
(grant reference 051210), the Agència de Gestiód’AjutsUniversitarisi de Recerca – Generalitat de 
Catalunya (grant reference 2014SRG756) who had no role in the data collection, analysis or 
interpretation of the results; the NIH (contract NO1-CO-12400); the Compagnia di San Paolo—
Programma Oncologia; the Federal Office for Radiation Protection grants StSch4261 and StSch4420, the 
José Carreras Leukemia Foundation grant DJCLS-R12/23, the German Federal Ministry for Education and 
Research (BMBF-01-EO-1303); the Health Research Board, Ireland and Cancer Research Ireland; Czech 
Republic supported by MH CZ – DRO (MMCI, 00209805) and MEYS - NPS I - LO1413; Fondation de France 
and Association de Recherche Contre le Cancer. GEC/Mayo GWAS - National Institutes of Health 
(CA118444, CA148690, CA92153). Intramural Research Program of the NIH, National Cancer Institute. 
Veterans Affairs Research Service. Data collection for Duke University was supported by a Leukemia & 
Lymphoma Society Career Development Award, the Bernstein Family Fund for Leukemia and Lymphoma 
Research, and the National Institutes of Health (K08CA134919), National Center for Advancing 
 26 
Translational Science (UL1 TR000135). [HPFS acknowledgment for any GWAS project that includes HPFS 
data:] HPFS (Walter C. Willet) – The HPFS was supported in part by National Institutes of Health grants 
UM1 CA167552, R01 CA149445, and R01 CA098122. We would like to thank the participants and staff of 
the Health Professionals Follow-up Study for their valuable contributions as well as the following state 
cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, 
NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY.  The authors assume full 
responsibility for analyses and interpretation of these data. The study protocol was approved by the 
institutional review boards of the Brigham and Women’s Hospital and Harvard T.H. Chan School of 
Public Health, and those of participating registries as required. Iowa-Mayo SPORE – NCI Specialized 
Programs of Research Excellence (SPORE) in Human Cancer (P50 CA97274); National Cancer Institute 
(P30 CA086862, P30 CA15083); Henry J. Predolin Foundation. Italian GxE - Italian Association for Cancer 
Research (AIRC, Investigator Grant 11855) (PC); Fondazione Banco di Sardegna 2010-2012, and Regione 
Autonoma della Sardegna (LR7 CRP-59812/2012) (MGE). Mayo Clinic Case-Control – National Institutes 
of Health (R01 CA92153); National Cancer Institute (P30 CA015083). MCCS – The Melbourne 
Collaborative Cohort Study recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS 
was further supported by Australian NHMRC grants 209057, 251553 and 504711 and by infrastructure 
provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian 
Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW), including the National 
Death Index and the Australian Cancer Database. MSKCC – Geoffrey Beene Cancer Research Grant, 
Lymphoma Foundation (LF5541); Barbara K. Lipman Lymphoma Research Fund (74419); Robert and Kate 
Niehaus Clinical Cancer Genetics Research Initiative (57470); U01 HG007033; ENCODE; U01 HG007033. 
NCI-SEER – Intramural Research Program of the National Cancer Institute, National Institutes of Health, 
and Public Health Service (N01-PC-65064,N01-PC-67008, N01-PC-67009, N01-PC-67010, N02-PC-71105). 
NHS (Meir J. Stampfer) – The NHS was supported in part by National Institutes of Health grants UM1 
CA186107, P01 CA87969, R01 CA49449, R01 CA149445 and R01 CA098122. We would like to thank the 
participants and staff of the Nurses' Health Study for their valuable contributions as well as the following 
state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, 
MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full 
responsibility for analyses and interpretation of these data. The study protocol was approved by the 
institutional review boards of the Brigham and Women’s Hospital and Harvard T.H. Chan School of 
Public Health, and those of participating registries as required. NSW - NSW was supported by grants 
from the Australian National Health and Medical Research Council (ID990920), the Cancer Council NSW, 
and the University of Sydney Faculty of Medicine. NYU-WHS - National Cancer Institute (R01 CA098661, 
P30 CA016087); National Institute of Environmental Health Sciences (ES000260).  PLCO - This research 
was supported by the Intramural Research Program of the National Cancer Institute and by contracts 
from the Division of Cancer Prevention, National Cancer Institute, NIH, DHHS. SCALE – Swedish Cancer 
Society (2009/659). Stockholm County Council (20110209) and the Strategic Research Program in 
Epidemiology at Karolinska Institutet. Swedish Cancer Society grant (02 6661). National Institutes of 
Health (5R01 CA69669-02); Plan Denmark. UCSF2 – The UCSF studies were supported by the NCI, 
National Institutes of Health, CA1046282 and CA154643. The collection of cancer incidence data used in 
this study was supported by the California Department of Health Services as part of the statewide 
cancer reporting program mandated by California Health and Safety Code Section 103885; the National 
Cancer Institute’s Surveillance, Epidemiology, and End Results Program under contract 
HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract 
HHSN261201000035C awarded to the University of Southern California, and contract 
HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and 
Prevention’s National Program of Cancer Registries, under agreement #1U58 DP000807-01 awarded to 
the Public Health Institute. The ideas and opinions expressed herein are those of the authors, and 
 27 
endorsement by the State of California, the California Department of Health Services, the National 
Cancer Institute, or the Centers for Disease Control and Prevention or their contractors and 
subcontractors is not intended nor should be inferred. UTAH - National Institutes of Health CA134674. 
Partial support for data collection at the Utah site was made possible by the Utah Population Database 
(UPDB) and the Utah Cancer Registry (UCR). Partial support for all datasets within the UPDB is provided 
by the Huntsman Cancer Institute (HCI) and the HCI Cancer Center Support grant, P30 CA42014. The 
UCR is supported in part by NIH contract HHSN261201000026C from the National Cancer Institute SEER 
Program with additional support from the Utah State Department of Health and the University of Utah. 
WHI – WHI investigators are: Program Office - (National Heart, Lung, and Blood Institute, Bethesda, 
Maryland) Jacques Rossouw, Shari Ludlam, Dale Burwen, Joan McGowan, Leslie Ford, and Nancy Geller;  
Clinical Coordinating Center - (Fred Hutchinson Cancer Research Center, Seattle, WA) Garnet Anderson, 
Ross Prentice, Andrea LaCroix, and Charles Kooperberg; Investigators and Academic Centers - (Brigham 
and Women's Hospital, Harvard Medical School, Boston, MA) JoAnn E. Manson; (MedStar Health 
Research Institute/Howard University, Washington, DC) Barbara V. Howard; (Stanford Prevention 
Research Center, Stanford, CA) Marcia L. Stefanick; (The Ohio State University, Columbus, OH) Rebecca 
Jackson; (University of Arizona, Tucson/Phoenix, AZ) Cynthia A. Thomson; (University at Buffalo, Buffalo, 
NY) Jean Wactawski-Wende; (University of Florida, Gainesville/Jacksonville, FL) Marian Limacher; 
(University of Iowa, Iowa City/Davenport, IA) Robert Wallace; (University of Pittsburgh, Pittsburgh, PA) 
Lewis Kuller; (Wake Forest University School of Medicine, Winston-Salem, NC) Sally Shumaker;  
Women’s Health Initiative Memory Study - (Wake Forest University School of Medicine, Winston-Salem, 
NC) Sally Shumaker. The WHI program is funded by the National Heart, Lung, and Blood Institute, 
National Institutes of Health, U.S. Department of Health and Human Services through contracts 
HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, 
HHSN268201100004C, and HHSN271201100004C. YALE – National Cancer Institute (CA62006); National 




The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research 
Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07).  The scientific 
development and funding for this project were in part supported by the US National Cancer Institute 
GAME-ON Post-GWAS Initiative (U19-CA148112).  This study made use of data generated by the 
Wellcome Trust Case Control consortium that was funded by the Wellcome Trust under award 076113.  
The results published here are in part based upon data generated by The Cancer Genome Atlas Pilot 
Project established by the National Cancer Institute and National Human Genome Research Institute 
(dbGap accession number phs000178.v8.p7).   
 
The OCAC OncoArray genotyping project was funded through grants from the U.S. National Institutes of 
Health (CA1X01HG007491-01 (C.I.A.), U19-CA148112 (T.A.S.), R01-CA149429 (C.M.P.) and R01-CA058598 
(M.T.G.); Canadian Institutes of Health Research (MOP-86727 (L.E.K.) and the Ovarian Cancer Research 
Fund (A.B.).  The COGS project was funded through a European Commission's Seventh Framework 
Programme grant (agreement number 223175 - HEALTH-F2-2009-223175).     
 
B.M. was supported by grant 17-44-020498, 17-29-06014 of the Russian Foundation for Basic 
Research.  D.P. was supported by grant 18-29-09129 of the Russian Foundation for Basic 
Research. E.K was supported by  the program for support the bioresource collections №007-
030164/2 and study was performed as part of the assignment of the Ministry of Science and Higher 
Education of Russian Federation (№АААА-А16-116020350032-1). 
 28 
 
Funding for individual studies:  
AAS: National Institutes of Health (RO1-CA142081); AUS: The Australian Ovarian Cancer Study (AOCS) 
was supported by the U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729), 
National Health & Medical Research Council of Australia (199600, 400413 and 400281), Cancer Councils 
of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of 
Western Australia (Multi-State Applications 191, 211 and 182). AOCS gratefully acknowledges additional 
support from Ovarian Cancer Australia and the Peter MacCallum Foundation; BAV: ELAN Funds of the 
University of Erlangen-Nuremberg; BEL: National Kankerplan; BGS: Breast Cancer Now, Institute of 
Cancer Research; BVU: Vanderbilt University Medical Center’s BioVU is supported by the 
1S10RR025141-01 instrumentation award and Vanderbilt CTSA grant from the National Institutes of 
Health (NIH)/National Center for Advancing Translational Sciences (NCATS) (ULTR000445); CAM: 
National Institutes of Health Research Cambridge Biomedical Research Centre and Cancer Research UK 
Cambridge Cancer Centre; CHA: Innovative Research Team in University (PCSIRT) in China (IRT1076); 
CNI: Instituto de Salud Carlos III (PI 12/01319); Ministerio de Economía y Competitividad (SAF2012); 
DKE: Ovarian Cancer Research Fund; DOV: National Institutes of Health R01-CA112523 and R01-
CA87538; EPC: The coordination of EPIC is financially supported by the European Commission (DG-
SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by 
Danish Cancer Society (Denmark) (EMC 2014-6699); Ligue Contre le Cancer, Institut Gustave Roussy, 
Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale 
(INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of 
Education and Research (BMBF) (Germany); the Hellenic Health Foundation (Greece); Associazione 
Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of 
Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch 
Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), 
Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of 
Excellence programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), PI13/00061 
to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, 
Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Research Council 
and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; 
C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, 
MR/M012190/1 to EPIC-Oxford) (United Kingdom); GER: German Federal Ministry of Education and 
Research, Programme of Clinical Biomedical Research (01 GB 9401)  and the German Cancer Research 
Center (DKFZ); GRC: This research has been co-financed by the European Union (European Social Fund - 
ESF) and Greek national funds through the Operational Program "Education and Lifelong Learning" of 
the National Strategic Reference Framework (NSRF) - Research Funding Program of the General 
Secretariat for Research & Technology: SYN11_10_19 NBCA. Investing in knowledge society through the 
European Social Fund; GRR: Roswell Park Cancer Institute Alliance Foundation, P30 CA016056; HAW: 
U.S. National Institutes of Health (R01-CA58598, N01-CN-55424 and N01-PC-67001); HJO: Intramural 
funding; Rudolf-Bartling Foundation; HMO: Intramural funding; Rudolf-Bartling Foundation; HOC: 
Helsinki University Hospital Research Fund; HOP: University of Pittsburgh School of Medicine Dean’s 
Faculty Advancement Award  (F. Modugno), Department of Defense (DAMD17-02-1-0669) and NCI (K07-
CA080668, R01-CA95023, P50-CA159981 MO1-RR000056 R01-CA126841); HUO: Intramural funding; 
Rudolf-Bartling Foundation; JPN: Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for 
Cancer Control from the Ministry of Health, Labour and Welfare; KRA: This study (Ko-EVE) was 
supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry 
Development Institute (KHIDI), and the National R&D Program for Cancer Control, Ministry of Health & 
Welfare, Republic of Korea (HI16C1127; 0920010); LAX: American Cancer Society Early Detection 
 29 
Professorship (SIOP-06-258-01-COUN) and the National Center for Advancing Translational Sciences 
(NCATS), Grant UL1TR000124; LUN: ERC-2011-AdG 294576-risk factors cancer, Swedish Cancer Society, 
Swedish Research Council, Beta Kamprad Foundation; MAC: National Institutes of Health (R01-
CA122443, P30-CA15083, P50-CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred 
C. and Katherine B. Andersen Foundation; Fraternal Order of Eagles; MAL: Funding for this study was 
provided by research grant R01- CA61107 from the National Cancer Institute, Bethesda, MD, research 
grant 94 222 52 from the Danish Cancer Society, Copenhagen, Denmark; and the Mermaid I project; 
MAS: Malaysian Ministry of Higher Education (UM.C/HlR/MOHE/06) and Cancer Research Initiatives 
Foundation; MAY: National Institutes of Health (R01-CA122443, P30-CA15083, P50-CA136393); Mayo 
Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; MCC: 
MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. Cancer Council Victoria, 
National Health and Medical Research Council of Australia (NHMRC) grants number 209057, 251533, 
396414, and 504715; MDA: DOD Ovarian Cancer Research Program (W81XWH-07-0449); MEC: NIH 
(CA54281, CA164973, CA63464); MOF: Moffitt Cancer Center, Merck Pharmaceuticals, the state of 
Florida, Hillsborough County, and the city of Tampa; NCO: National Institutes of Health (R01-CA76016) 
and the Department of Defense (DAMD17-02-1-0666); NEC: National Institutes of Health R01-CA54419 
and P50-CA105009 and Department of Defense W81XWH-10-1-02802; NHS: UM1 CA186107, P01 
CA87969, R01 CA49449, R01-CA67262, UM1 CA176726; NOR: Helse Vest, The Norwegian Cancer 
Society, The Research Council of Norway; NTH: Radboud University Medical Centre; OPL: National 
Health and Medical Research Council (NHMRC) of Australia (APP1025142) and Brisbane Women's Club; 
ORE: OHSU Foundation; OVA: This work was supported by Canadian Institutes of Health Research grant 
(MOP-86727) and by NIH/NCI 1 R01CA160669-01A1; PLC: Intramural Research Program of the National 
Cancer Institute; POC: Pomeranian Medical University; POL: Intramural Research Program of the 
National Cancer Institute; PVD: Canadian Cancer Society and Cancer Research Society GRePEC Program; 
RBH: National Health and Medical Research Council of Australia; RMH: Cancer Research UK, Royal 
Marsden Hospital; RPC: National Institute of Health (P50 CA159981, R01CA126841); SEA: Cancer 
Research UK (C490/A10119 C490/A10124); UK National Institute for Health Research Biomedical 
Research Centres at the University of Cambridge; SIS: The Sister Study (SISTER) is supported by the 
Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01-
ES044005 and Z01-ES049033); SMC: The Swedish Cancer Foundation and the Swedish Research Council 
(VR 2017-00644) grant for the Swedish Infrastructure for Medical Population-based Life-course 
Environmental Research (SIMPLER); SRO: Cancer Research UK (C536/A13086, C536/A6689) and Imperial 
Experimental Cancer Research Centre (C1312/A15589); STA: NIH grants U01 CA71966 and U01 
CA69417; SWH: NIH (NCI) grant R37-CA070867; TBO: National Institutes of Health (R01-CA106414-A2), 
American Cancer Society (CRTG-00-196-01-CCE), Department of Defense (DAMD17-98-1-8659), Celma 
Mastery Ovarian Cancer Foundation; TOR: NIH grants R01 CA063678 and R01 CA063682; UCI: NIH R01-
CA058860 and the Lon V Smith Foundation grant LVS-39420; UHN: Princess Margaret Cancer Centre 
Foundation-Bridge for the Cure; UKO: The UKOPS study was funded by The Eve Appeal (The Oak 
Foundation) and supported by the National Institute for Health Research University College London 
Hospitals Biomedical Research Centre; UKR: Cancer Research UK (C490/A6187), UK National Institute for 
Health Research Biomedical Research Centres at the University of Cambridge; USC: P01CA17054, 
P30CA14089, R01CA61132, N01PC67010, R03CA113148, R03CA115195, N01CN025403, and  California 
Cancer Research Program (00-01389V-20170, 2II0200); VAN: BC Cancer Foundation, VGH & UBC 
Hospital Foundation; VTL: NIH K05-CA154337; WMH: National Health and Medical Research Council of 
Australia, Enabling Grants ID 310670 & ID 628903. Cancer Institute NSW Grants 12/RIG/1-17 & 
15/RIG/1-16; WOC: National Science Centre (N N301 5645 40), The Maria Sklodowska-Curie Memorial 




We are grateful to the family and friends of Kathryn Sladek Smith for their generous support of the 
Ovarian Cancer Association Consortium through their donations to the Ovarian Cancer Research 
Fund. The OncoArray and COGS genotyping projects would not have been possible without the 
contributions of the following: Per Hall (COGS); Kyriaki Michailidou, Manjeet K. Bolla, Qin Wang (BCAC), 
(OCAC), Rosalind A. Eeles, Ali Amin Al Olama, Zsofia  Kote-Jarai, Sara Benlloch (PRACTICAL), Antonis 
Antoniou, Lesley McGuffog, Fergus Couch and Ken Offit (CIMBA), Alison M. Dunning, Andrew Lee, and 
Ed Dicks, Craig Luccarini and the staff of the Centre for Genetic Epidemiology Laboratory, Anna 
Gonzalez-Neira and the staff of the CNIO genotyping unit, Jacques Simard and Daniel C. Tessier, Francois 
Bacot, Daniel Vincent, Sylvie LaBoissière and Frederic Robidoux and the staff of the McGill University 
and Génome Québec Innovation Centre, Stig E. Bojesen, Sune F. Nielsen, Borge G. Nordestgaard, and 
the staff of the Copenhagen DNA laboratory, and Julie M. Cunningham, Sharon A. Windebank, 
Christopher A. Hilker, Jeffrey Meyer and the staff of Mayo Clinic Genotyping Core Facility. We pay 
special tribute to the contribution of Professor Brian Henderson to the GAME-ON consortium; to Olga 
M. Sinilnikova for her contribution to CIMBA and for her part in the initiation and coordination of GEMO 
until she sadly passed away on 30th June 2014 and to Catherine M. Phelan for her contribution to OCAC 
and the coordination of the OncoArray until she passed away on 22 September 2017. We thank the 
study participants, doctors, nurses, clinical and scientific collaborators, health care providers and health 
information sources who have contributed to the many studies contributing to this manuscript.   
 
Acknowledgements for individual studies: 
AUS: The AOCS also acknowledges the cooperation of the participating institutions in Australia, and the 
contribution of the study nurses, research assistants and all clinical and scientific collaborators. The 
complete AOCS Study Group can be found at www.aocstudy.org. We would like to thank all of the 
women who participated in this research program; BEL: We would like to thank Gilian Peuteman, 
Thomas Van Brussel, Annick Van den Broeck and Joke De Roover for technical assistance; BGS: The 
Institute of Cancer Research (ICR) acknowledges NHS funding to the NIHR Biomedical Research Centre. 
We thank the Study staff, study participants , doctors, nurses, health care providers and health 
information sources who have contributed to the study; BVU: The dataset(s) used for the analyses 
described were obtained from Vanderbilt University Medical Center’s BioVU; CHA: Innovative Research 
Team in University (PCSIRT) in China (IRT1076); CHN: To thank all members of Department of Obstetrics 
and Gynaecology, Hebei Medical University, Fourth Hospital and Department of Molecular Biology, 
Hebei Medical University, Fourth Hospital; EPC: To thank all members and investigators of the 
Rotterdam Ovarian Cancer Study; GER: The German Ovarian Cancer Study (GER) thanks Ursula Eilber for 
competent technical assistance; MAS: We would like to thank Famida Zulkifli and Ms Moey for 
assistance in patient recruitment, data collection and sample preparation; MCC: Cases and their vital 
status were ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute of 
Health and Welfare (AIHW), including the National Death Index and the Australian Cancer Database; 
MOF: the Total Cancer Care™ Protocol and the Collaborative Data Services and Tissue Core Facilities at 
the H. Lee Moffitt Cancer Center & Research Institute, an NCI designated Comprehensive Cancer Center 
(P30-CA076292), Merck Pharmaceuticals and the state of Florida; NHS: The NHS/NHSII studies thank the 
following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, 
ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY; OPL: 
Members of the OPAL Study Group (http://opalstudy.qimrberghofer.edu.au/); SEA: SEARCH team, Craig 
Luccarini, Caroline Baynes, Don Conroy; SRO: To thank all members of Scottish Gynaecological Clinical 
Trails group and SCOTROC1 investigators; SWH: We thank the participants and the research staff of the 
Shanghai Women’s Health Study for making this study possible; UHN: Princess Margaret Cancer Centre 
Foundation-Bridge for the Cure; UKO: We particularly thank I. Jacobs, M.Widschwendter, E. Wozniak, A. 
 31 
Ryan, J. Ford and N. Balogun for their contribution to the study; UKR: Carole Pye; VAN: BC Cancer 
Foundation, VGH & UBC Hospital Foundation; WMH: We thank the Gynaecological Oncology Biobank at 
Westmead, a member of the Australasian Biospecimen Network-Oncology group. 
 
Oral Cancer GWAS 
Oral cancer GWAS Genotyping performed at the Center for Inherited Disease Research (CIDR) was 




This work was supported by RO1 CA 154823. Genotyping Services were provided by the Center for 
Inherited Disease Research (CIDR).  CIDR is fully funded through a federal contract from the National 
Institutes of Health to the Johns Hopkins University, contract number HHSN268201100011I. 
 
The IARC/Central Europe study was supported by a grant from the US National Cancer Institute at the 
National Institutes of Health (R03 CA123546-02) and grants from the Ministry of Health of the Czech 
Republic (NR 9029-4/2006, NR9422-3, NR9998-3, MH CZ-DRO-MMCI  00209805). The work at Johns 
Hopkins University was supported by the NCI Grants P50CA062924 and R01CA97075. The Mayo Clinic 
Biospecimen Resource for Pancreas Research study is supported by the Mayo Clinic SPORE in 
Pancreatic Cancer (P50 CA102701). The Memorial Sloan Kettering Cancer Center Pancreatic Tumor 
Registry is supported by P30CA008748, the Geoffrey Beene Foundation, the Arnold and Arlene 
Goldstein Family Foundation, and the Society of MSKCC. The Queensland Pancreatic Cancer Study was 
supported by a grant from the National Health and Medical Research Council of Australia (NHMRC) 
(Grant number 442302). RE Neale is supported by a NHMRC Senior Research Fellowship (#1060183). 
SELECT: Research reported in this publication was supported in part by the National Cancer Institute of 
the National Institutes of Health under Award Numbers U10 CA37429 (CD Blanke), and UM1 CA182883 
(CM Tangen/IM Thompson). The content is solely the responsibility of the authors and does not 
necessarily represent the official views of the National Institutes of Health. The UCSF pancreas study 
was supported by NIH-NCI grants (R01CA1009767, R01CA109767-S1) and the Joan Rombauer Pancreatic 
Cancer Fund. Collection of cancer incidence data was supported by the California Department of Public 
Health as part of the statewide cancer reporting program; the NCI’s SEER Program under contract 
HHSN261201000140C awarded to CPIC; and the CDC’s National Program of Cancer Registries, under 
agreement #U58DP003862-01 awarded to the California Department of Public Health. The Yale (CT) 
pancreas study is supported by National Cancer Institute at the U.S. National Institutes of Health, grant 
5R01CA098870. The cooperation of 30 Connecticut hospitals, including Stamford Hospital, in allowing 
patient access, is gratefully acknowledged.  The Connecticut Pancreas Cancer Study was approved by the 
State of Connecticut Department of Public Health Human Investigation Committee.  Certain data used in 
that study were obtained from the Connecticut Tumor Registry in the Connecticut Department of Public 
Health. The authors assume full responsibility for analyses and interpretation of these data. 
 
PanScan 
The work conducted at NCI was supported by the Intramural Research Program (IRP) of the Division of 
Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health (NIH). The 
work conducted at the Vanderbilt University Medical Center was supported in part by R01CA188214 
and K99CA218892. The Melbourne Collaborative Cohort Study cohort recruitment was funded by 
VicHealth and Cancer Council Victoria. The MCCS was further augmented by Australian National Health 
and Medical Research Council grants 209057, 396414 and 1074383 and by infrastructure provided by 
Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer 
 32 
Registry and the Australian Institute of Health and Welfare, including the National Death Index and the 
Australian Cancer Database. The WHI program is funded by the National Heart, Lung, and Blood 
Institute, National Institutes of Health, U.S. Department of Health and Human Services through 
contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, 
and HHSN268201600004C. For a list of WHI investigators contributed to WHI science, please visit: 
https://www.whi.org/researchers/SitePages/Principal%20Investigators.aspx. Cancer incidence data for 
CLUE were provided by the Maryland Cancer Registry, Center for Cancer Surveillance and Control, 
Department of Health and Mental Hygiene, 201 W. Preston Street, Room 400, Baltimore, MD 21201, 
http://phpa.dhmh.maryland.gov/cancer, 410-767-4055. We acknowledge the State of Maryland, the 
Maryland Cigarette Restitution Fund, and the National Program of Cancer Registries of the Centers for 
Disease Control and Prevention for the funds that support the collection and availability of the cancer 
registry data.” We thank all the CLUE participants. The NYU study was funded by NIH R01 CA098661, 
UM1 CA182934 and center grants P30 CA016087 and P30 ES000260. The Physicians' Health Study was 
supported by research grants CA-097193, CA-34944, CA40360, HL-26490, and HL-34595 from the 
National Institutes of Health, Bethesda, MD USA. The Women's Health Study was supported by research 
grants CA-047988, HL-043851, HL080467, and HL-099355 from the National Institutes of Health, 
Bethesda, MD USA. Health Professionals Follow-up Study is supported by NIH grant UM1 CA167552 
from the National Cancer Institute, Bethesda, MD USA. Nurses’ Health Study is supported by NIH grants 
UM1 CA186107, and R01 CA49449 from the National Cancer Institute, Bethesda, MD USA. The PANKRAS 
II Study in Spain was supported by research grants from Instituto de Salud Carlos III-FEDER, Spain: Fondo 
de Investigaciones Sanitarias (FIS) ((#PI95/0017, #PI12/00815, #PI13/00082 and #PI15/01573), Red 
Temática de Investigación Cooperativa en Cáncer (#RD12/0036/0050), and CIBER de Epidemiología 
(CIBERESP); Ministerio de Ciencia y Tecnología (CICYT SAF 2000-0097); Generalitat de Catalunya (CIRIT - 
SGR), Spain. The IARC/Central Europe study was supported by a grant from the US National Cancer 
Institute at the National Institutes of Health (R03 CA123546-02) and grants from the Ministry of Health 
of the Czech Republic (NR 9029-4/2006, NR9422-3, NR9998-3, MH CZDRO-MMCI 00209805). 
 
PRACTICAL, CRUK, BPC3, CAPS, PEGASUS 
CRUK and PRACTICAL consortium: 
This work was supported by the Canadian Institutes of Health Research, European Commission's 
Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175),  Cancer 
Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, 
C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 
1 U19 CA 148537-01 (the GAME-ON initiative).     
 
We would also like to thank the following for funding support: The Institute of Cancer Research and The 
Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now 
PCUK), The Orchid Cancer Appeal, Rosetrees Trust, The National Cancer Research Network UK, The 
National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR 
Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation 
Trust.   
 
The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The 
National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 
504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate 
Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. 
EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research 
Institute for their support.  
 33 
 
Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 
for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the 
Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I]. Additional 
analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher). 
 
Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework 
Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK 
(C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, 
C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS 
initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the 
Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the 
CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer 
Research Foundation, and the Ovarian Cancer Research Fund. 
 
BPC3: The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute 
(cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 toE.R., and 
U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of 
Cancer Epidemiology and Genetics). 
 
CAPS: CAPS GWAS study was supported by the Cancer Risk Prediction Center (CRisP; 
www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research 
Council, (grant no K2010-70X-20430-04-3), the Swedish Cancer Foundation (grant no 09-0677), the 
Hedlund Foundation, the Soederberg Foundation, the Enqvist Foundation, ALF funds from the 
Stockholm County Council. Stiftelsen Johanna Hagstrand och Sigfrid Linner's Minne, Karlsson's Fund for 
urological and surgical research. 
 
PEGASUS: PEGASUS was supported by the Intramural Research Program, Division of Cancer 
Epidemiology and Genetics, National Cancer Institute, National Institutes of Health. 
 
Renal Cancer GWAS 
AHS: This research was supported by the Intramural Research Program of the NIH, National Cancer 
Institute, Division of Cancer Epidemiology and Genetics (Z01CP010119).ATBC: The ATBC Study was 
supported by funding provided by the Intramural Research Program of the NCI, NIH, and through U.S. 
Public Health Service contracts (N01-CN-45165, N01-RC-45035 and N01-RC-37004) from the NCI. BioVU: 
The dataset used in the analyses described were obtained from the Vanderbilt University Medical 
Center resource BioVU, which is supported by institutional funding, the 1S10RR025141-01 
instrumentation award, and by the Vanderbilt CTSA grant UL1 TR000445 from NCATS/NIH. 
Sample processing and phenotyping algorithm development was supported by institutional 
funding for TLE. Center ‘Bioengineering’ of the Russian Academy of Sciences/Kurchatov Scientific 
Center: The work conducted for this study was supported by the grant Russian Scientific Fund 14-14- 
01202. Centre National de Genotypage, France: We thank Jean Guillaume Garnier and Delphine Bacq-
Daian for their work on the IARC-2 scan. ConFIRM/MCCS: The ConFIRM study, also known as CARES, 
was supported by the Victorian Cancer Agency (PTCB08_05), the Australian National Health and Medical 
Research Council (Project Grant 1011626). We acknowledge the contribution of Professor Graham Giles 
in supporting this work and of Ms Olive Schmid and Ms Jennifer Walsh for the project management. The 
Melbourne Collaborative Cohort Study (MCCS) recruitment was funded by VicHealth and Cancer Council 
Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553 and 504711 and 
 34 
by infrastructure provided by Cancer Council Victoria. CPS-II: The Cancer Prevention Study II Nutrition 
Cohort is supported by the American Cancer Society. The authors thank all of the men and women in the 
Cancer Prevention Study II Nutrition Cohort for their many years of dedicated participation in the study. 
Health Professionals Follow-up Study (HPFS) and Nurses’ Health Study (NHS): The HPFS is supported by 
National Institutes of Health, National Cancer Institute grant UM1CA167552. The NHS is supported by 
National Institutes of Health, National Cancer Institute grants UM1 CA186107 and P01 CA87969. We 
would like to thank the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, 
ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, 
WY. The authors assume full responsibility for analyses and interpretation of these data. K2 study: This 
study was supported by the EU FP7 under grant agreement number 241669 (the CAGEKID project). In 
Czech Republic, this work was also supported by MH CZ—DRO (MMCI, 00209805) and by the project 
MEYS – NPS I – LO1413, Czech Republic. Leeds Cohort: The infrastructure support from Cancer Research 
UK as part of the Leeds Centre and Experimental Cancer Medicine Centre funding is gratefully 
acknowledged together with the Leeds Multidisciplinary Research Tissue Bank, all patients who 
consented to take part in the research studies and the staff of the Urology and Oncology Departments in 
Leeds Teaching Hospitals Trust. Mayo Clinic: This study was partially supported by National Institutes of 
Health: R21CA176422 (JEEP) and R01CA134466 (ASP). The authors acknowledge the Mayo Clinic 
Comprehensive Cancer Center Biospecimens Accessioning and Processing Shared Resource and the 
Pathology Research Core Shared Resource. MD Anderson: This work was supported in part by the NIH 
(grant R01 CA170298) and the Center for Translational and Public Health Genomics, Duncan Family 
Institute for Cancer Prevention and Risk Assessment, The University of Texas MD Anderson Cancer 
Center. NCI/IARC RCC Study in Central Europe (CE): This project was supported by the Intramural 
Research Program of the NIH and the National Cancer Institute. Physicians’ Health Study (PHS): This 
study was supported by grants CA 097193, CA 34944, CA 40360, HL 26490, and HL 34595 from the 
National Institutes of Health, Bethesda, MD. PLCO: This research was supported by the Intramural 
Research Program of the National Cancer Institute and by contracts from the Division of Cancer 
Prevention, National Cancer Institute, NIH, DHHS. SEARCH: This study is funded by Cancer Research UK 
(C490/A16651). UK GWAS: We acknowledge support from the Medical Research Council (MRC), Cancer 
Research UK, an educational grant from Bayer and NHS funding for the Royal Marsden Biomedical 
Research Centre and Cambridge University Health Partners. JL is supported by the NIHR RM/CR 
Biomedical Research Centre for Cancer. US Kidney Cancer Study: The NCI United Stated Kidney Cancer 
Study was supported by the Intramural Research Program of the National Institutes of Health and the 
National Cancer Institute under the following contracts: N02-CP-10128 (Westat, Inc.), N02-CP-11004 
(Wayne State University), and N02-CP- 11161 (University of Illinois at Chicago). Van Andel Research 
Institute (VARI): The authors would like to thank Dr. Kyle Furge for his role in this project as well as Drs. 
Anthony Avallone, John Ludlow and Philip Wise for contributing samples for this project. Women’s 
Health Initiative (WHI): The WHI program is funded by the National Heart, Lung, and Blood Institute, 
National Institutes of Health, U.S. Department of Health and Human Services through contracts 
HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, 
HHSN268201100004C, and HHSN271201100004C. For a list of all the investigators who have contributed 
to WHI science, please visit: 
https://www.whi.org/researchers/SitePages/Principal%20Investigators.aspx. Women’s Health Study 
(WHS): The study is supported by grants CA-047988, HL-043851, HL-080467, HL-099355, and 
UM1CA182913 from the National Institutes of Health, Bethesda, MD. 
 
TECAC 
This work was supported by the Testicular Cancer Consortium (TECAC) funded by the National Cancer 
Institute under Grant no. R01 CA164947. The TECAC is an international collaborative effort between the 
 35 
National Cancer Institute (USA), The University of Pennsylvania (USA), Copenhagen University Hospital, 
Rigshospitalet (Denmark), Spanish National Cancer Research Center (Spain), University of Leeds (UK), 
University of Southern California (USA), University of Brescia (Italy), University Medical Center 
Groningen (The Netherlands), Cancer Registry of Norway (Norway), Princess Margaret Cancer Center 
(Canada), Harvard School of Public Health (USA), MD Anderson Cancer Center (USA), Moffitt Cancer 
Center (USA), Radboud University Medical Center, Nijmegen (The Netherlands), University Medical 
Center, Hamburg-Eppendorf (Germany), deCODE Genetics (Iceland), University of Turin (Italy), Fred 
Hutchinson Cancer Research Center (USA), Institute for Cancer Research (Norway), Institute of Cancer 
Research (UK), Karolinska Institute (Sweden),and Brown University (USA). 
 36 
3.2 CONSORTIUM-SPECIFIC COLLABORATORS 
 
BCAC 
Thomas Ahearn1, Irene L. Andrulis2,3, Hoda Anton-Culver4, Natalia N. Antonenkova5, Volker 
Arndt6, Kristan J. Aronson7, Paul L. Auer8,9, Annelie Augustinsson10, Heiko Becher11, Matthias W. 
Beckmann12, Marina Bermisheva13, Carl Blomqvist14,15, Natalia V. Bogdanova16,17,5, Stig E. 
Bojesen18,19,20, Manjeet K. Bolla21, Bernardo Bonanni22, Hiltrud Brauch23,24,25, Hermann 
Brenner26,27,25, Annegien Broeks28, Sara Y. Brucker29, Thomas Brüning30, Barbara Burwinkel31,32, Federico 
Canzian33, Jose E. Castelao34, Christine L. Clarke35, Fergus J. Couch36, Kamila Czene37, Mary B. 
Daly38, Peter Devilee39,40, Thilo Dörk17, Isabel dos-Santos-Silva41, Alison M. Dunning42, Miriam 
Dwek43, Diana M. Eccles44, A. Heather Eliassen45,46, Peter A. Fasching47,12, Henrik Flyger48, Lin 
Fritschi49, Manuela Gago-Dominguez50,51, Susan M. Gapstur52, José A. García-Sáenz53, Mia M. 
Gaudet52, Graham G. Giles54,55,56, Mark S. Goldberg57,58, David E. Goldgar59, Pascal Guénel60, Eric 
Hahnen61,62, Niclas Håkansson63, Ute Hamann64, Steven N. Hart65, Bernadette A.M. Heemskerk-
Gerritsen66, Peter Hillemanns67, Antoinette Hollestelle66, Maartje J. Hooning66, John L. Hopper55, David J. 
Hunter68,46,69, ABCTB Investigators70, Anna Jakubowska71,72, Wolfgang Janni73, Esther M. John74, Audrey 
Jung75, Rudolf Kaaks75, Pooja M. Kapoor75,76, Elza Khusnutdinova77,13, Veli-Matti Kosma78,79,80, Vessela N. 
Kristensen81,82, Katerina Kubelka-Sabit83, Allison W. Kurian74,84, Diether Lambrechts85,86, Loic Le 
Marchand87, Annika Lindblom88,89, Sibylle Loibl90, Jan Lubiński71, Michael P. Lux91, Arto 
Mannermaa78,79,80, Mehdi Manoochehri64, Sara Margolin92,93, Dimitrios Mavroudis94, Usha 
Menon95, Anna Marie. Mulligan96,97, NBCS Collaborators98,99,100,101,102,103,104,105,106,107,108,109, Susan L. 
Neuhausen110, Heli Nevanlinna111, Katie M. O'Brien112, Håkan Olsson10, Nick Orr113, Julian Peto41, Dijana 
Plaseska-Karanfilska114, Ross Prentice8, Nadege Presneau43, Brigitte Rack73, Paolo Radice115, Gad 
Rennert116, Hedy S. Rennert116, Atocha Romero117, Matthias Ruebner91, Emmanouil Saloustros118, Dale P. 
Sandler112, Rita K. Schmutzler61,62, Lukas Schwentner73, Christopher Scott65, Priyanka Sharma119, Xiao-Ou 
Shu120, Christof Sohn121, Melissa C. Southey56,122,123, John J. Spinelli124,125, Jennifer Stone126,55, Anthony J. 
Swerdlow127,128, Rulla M. Tamimi45,46,68, William J. Tapper44, Jack A. Taylor112,129, Mary Beth 
Terry130, Amanda E. Toland131, Thérèse Truong60, Michael Untch132, Celine M. Vachon133, Qin 
Wang21, Clarice R. Weinberg134, Hans Wildiers135, Alicja Wolk63,136, Xiaohong R. Yang1, Wei 
Zheng120, Argyrios Ziogas4 
 
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human 
Services, Bethesda, MD, USA, 2Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, 
Toronto, ON, Canada, 3Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada, 4Department of Epidemiology, Genetic 
Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA, 5N.N. Alexandrov Research Institute of Oncology and Medical 
Radiology, Minsk, Belarus, 6Division of Clinical Epidemiology and Aging Research, C070, German Cancer Research Center (DKFZ), Heidelberg, 
Germany, 7Department of Public Health Sciences, and Cancer Research Institute, Queen’s University, Kingston, ON, Canada, 8Cancer Prevention 
Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 9Zilber School of Public Health, University of Wisconsin-Milwaukee, 
Milwaukee, WI, USA, 10Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund, Sweden, 11Institute for Medical Biometrics 
and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 12Department of Gynecology and Obstetrics, 
Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, 
Germany, 13Institute of Biochemistry and Genetics, Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, Russia, 14Department 
of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, 15Department of Oncology, Örebro University Hospital, 
Örebro, Sweden, 16Department of Radiation Oncology, Hannover Medical School, Hannover, Germany, 17Gynaecology Research Unit, Hannover 
Medical School, Hannover, Germany, 18Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, 
Herlev, Denmark, 19Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, 
Denmark, 20Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, 21Centre for Cancer Genetic 
Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK, 22Division of Cancer Prevention and 
Genetics, IEO, European Institute of Oncology IRCCS, Milan, Italy, 23Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, 
Germany, 24iFIT-Cluster of Excellence, Germany, University of Tuebingen, Tuebingen, Germany, 25German Cancer Consortium (DKTK), German 
Cancer Research Center (DKFZ), Heidelberg, Germany, 26Division of Clinical Epidemiology and Aging Research, German Cancer Research Center 
(DKFZ), Heidelberg, Germany, 27Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor 
Diseases (NCT), Heidelberg, Germany, 28Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 
 37 
Amsterdam, The Netherlands, 29Department of Gynecology and Obstetrics, University of Tübingen, Tübingen, Germany, 30Institute for 
Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, 
Germany, 31Molecular Epidemiology Group, C080, German Cancer Research Center (DKFZ), Heidelberg, Germany, 32Molecular Biology of Breast 
Cancer, University Womens Clinic Heidelberg, University of Heidelberg, Heidelberg, Germany, 33Genomic Epidemiology Group, German Cancer 
Research Center (DKFZ), Heidelberg, Germany, 34Oncology and Genetics Unit, Instituto de Investigacion Sanitaria Galicia Sur (IISGS), Xerencia de 
Xestion Integrada de Vigo-SERGAS, Vigo, Spain, 35Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, 
Australia, 36Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA, 37Department of Medical Epidemiology and 
Biostatistics, Karolinska Institutet, Stockholm, Sweden, 38Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, 
USA, 39Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands, 40Department of Human Genetics, Leiden 
University Medical Center, Leiden, The Netherlands, 41Department of Non-Communicable Disease Epidemiology, London School of Hygiene and 
Tropical Medicine, London, UK, 42Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, 
UK, 43School of Life Sciences, University of Westminster, London, UK, 44Faculty of Medicine, University of Southampton, Southampton, 
UK, 45Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, 
MA, USA, 46Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA, 47David Geffen School of Medicine, 
Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, CA, USA, 48Department of 
Breast Surgery, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark, 49School of Public Health, Curtin University, 
Perth, Western Australia, Australia, 50Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de Investigación Sanitaria 
de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain, 51Moores Cancer 
Center, University of California San Diego, La Jolla, CA, USA, 52Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, 
GA, USA, 53Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro 
Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain, 54Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, 
Victoria, Australia, 55Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of 
Melbourne, Melbourne, Victoria, Australia, 56Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, 
Victoria, Australia, 57Department of Medicine, McGill University, Montréal, QC, Canada, 58Division of Clinical Epidemiology, Royal Victoria 
Hospital, McGill University, Montréal, QC, Canada, 59Department of Dermatology, Huntsman Cancer Institute, University of Utah School of 
Medicine, Salt Lake City, UT, USA, 60Cancer & Environment Group, Center for Research in Epidemiology and Population Health (CESP), INSERM, 
University Paris-Sud, University Paris-Saclay, Villejuif, France, 61Center for Hereditary Breast and Ovarian Cancer, Faculty of Medicine and 
University Hospital Cologne, University of Cologne, Cologne, Germany, 62Center for Integrated Oncology (CIO), Faculty of Medicine and 
University Hospital Cologne, University of Cologne, Cologne, Germany, 63Institute of Environmental Medicine, Karolinska Institutet, Stockholm, 
Sweden, 64Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany, 65Department of Health 
Sciences Research, Mayo Clinic, Rochester, MN, USA, 66Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, 
Rotterdam, The Netherlands, 67Gynaecology Research Unit, Hannover Medical School, Hannover, Germany, 68Program in Genetic Epidemiology 
and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA, 69Nuffield Department of Population Health, University of 
Oxford, Oxford, UK, 70Australian Breast Cancer Tissue Bank, Westmead Institute for Medical Research, University of Sydney, Sydney, New South 
Wales, Australia, 71Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland, 72Independent Laboratory of 
Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland, 73Department of Gynaecology and Obstetrics, 
University Hospital Ulm, Ulm, Germany, 74Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School 
of Medicine, Standford, CA, USA, 75Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, 76Faculty of 
Medicine, University of Heidelberg, Heidelberg, Germany, 77Department of Genetics and Fundamental Medicine, Bashkir State Medical 
University, Ufa, Russia, 78Translational Cancer Research Area, University of Eastern Finland, Kuopio, Finland, 79Institute of Clinical Medicine, 
Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland, 80Imaging Center, Department of Clinical Pathology, Kuopio 
University Hospital, Kuopio, Finland, 81Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital-
Radiumhospitalet, Oslo, Norway, 82Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway, 83Department of 
Histopathology and Cytology, Clinical Hospital Acibadem Sistina, Skopje, Republic of North Macedonia, 84Department of Health Research and 
Policy - Epidemiology, Stanford University School of Medicine, Standford, CA, USA, 85VIB Center for Cancer Biology, VIB, Leuven, 
Belgium, 86Laboratory for Translational Genetics, Department of Human Genetics, University of Leuven, Leuven, Belgium, 87Epidemiology 
Program, University of Hawaii Cancer Center, Honolulu, HI, USA, 88Department of Molecular Medicine and Surgery, Karolinska Institutet, 
Stockholm, Sweden, 89Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden, 90German Breast Group, GmbH, Neu 
Isenburg, Germany, 91Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-
Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, 92Department of Oncology, Södersjukhuset, Stockholm, 
Sweden, 93Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, 94Department of Medical 
Oncology, University Hospital of Heraklion, Heraklion, Greece, 95MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, 
University College London, London, UK, 96Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, 
Canada, 97Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, 98Department of Cancer Genetics, Institute for 
Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, 99Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 
Oslo, 100Department of Research, Vestre Viken Hospital, Drammen, Norway, 101Department of Cancer Genetics, Vestre Viken Hospital, 
Drammen, Norway, 102Section for Breast- and Endocrine Surgery, Department of Cancer, Division of Surgery, Cancer and Transplantation 
Medicine, Oslo University Hospital-Ullevål, Oslo, Norway, 103Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, 
Norway, 104Department of Pathology, Akershus University Hospital, Lørenskog, Norway, 105Department of Tumor Biology, Institute for Cancer 
Research, Oslo University Hospital, Oslo, Norway, 106Department of Oncology, Division of Surgery, Cancer and Transplantation Medicine, Oslo 
University Hospital-Radiumhospitalet, Oslo, Norway, 107National Advisory Unit on Late Effects after Cancer Treatment, Oslo University Hospital-
Radiumhospitalet, Oslo, Norway, 108Department of Oncology, Akershus University Hospital, Lørenskog, Norway, 109Breast Cancer Research 
Consortium, Oslo University Hospital, Oslo, Norway, 110Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, 
CA, USA, 111Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, 112Epidemiology 
Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA, 113Centre for Cancer Research and Cell 
Biology, Queen's University Belfast, Belfast, Ireland, 114Research Centre for Genetic Engineering and Biotechnology "Georgi D. Efremov", 
 38 
Macedonian Academy of Sciences and Arts, Skopje, Republic of North Macedonia, 115Unit of Molecular Bases of Genetic Risk and Genetic 
Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy, 116Clalit National Cancer Control Center, 
Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel, 117Medical Oncology Department, Hospital Universitario Puerta de 
Hierro, Madrid, Spain, 118Department of Oncology, University Hospital of Larissa, Larissa, Greece, 119Department of Internal Medicine, Division 
of Medical Oncology, University of Kansas Medical Center, Westwood, KS, USA, 120Division of Epidemiology, Department of Medicine, 
Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA, 121National 
Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany, 122Department of Clinical Pathology, 
The University of Melbourne, Melbourne, Victoria, Australia, 123Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, 
Australia, 124Population Oncology, BC Cancer, Vancouver, BC, Canada, 125School of Population and Public Health, University of British Columbia, 
Vancouver, BC, Canada, 126The Curtin UWA Centre for Genetic Origins of Health and Disease, Curtin University and University of Western 
Australia, Perth, Western Australia, Australia, 127Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
UK, 128Division of Breast Cancer Research, The Institute of Cancer Research, London, UK, 129Epigenetic and Stem Cell Biology Laboratory, 
National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA, 130Department of Epidemiology, Mailman School of 
Public Health, Columbia University, New York, NY, USA, 131Department of Cancer Biology and Genetics, The Ohio State University, Columbus, 
OH, USA, 132Department of Gynecology and Obstetrics, Helios Clinics Berlin-Buch, Berlin, Germay, 133Department of Health Science Research, 
Division of Epidemiology, Mayo Clinic, Rochester, MN, USA, 134Biostatistics and Computational Biology Branch, National Institute of 
Environmental Health Sciences, NIH, Research Triangle Park, NC, USA, 135Leuven Multidisciplinary Breast Center, Department of Oncology, 
Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium, 136Department of Surgical Sciences, Uppsala University, Uppsala, Sweden 
 
BEACON 
Lesley A. Anderson1, Leslie Bernstein2, Nigel C. Bird3, Wong-Ho Chow4, Doug A. Corley5, Rebecca C. 
Fitzgerald6, Marilie D. Gammon7, Laura J. Hardie8, Prasad G. Iyer9, Jesper Lagergren10,11, Geoffrey 
Liu12, Brian J. Reid13, Harvey A. Risch14, Nick J. Shaheen15, Tom L. Vaughan16, Anna H. Wu17,18, Weimin 
Ye19 
 
1Centre for Public Health, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, UK, 2Division of Biomarkers 
of Early Detection and Prevention, Beckman Research Institute, City of Hope, Duarte, CA, USA, 3Department of Oncology, Medical School, 
University of Sheffield, Sheffield, UK, 4Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 
USA, 5Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA, 6Medical Research Council Cancer Unit, Hutchison-MRC 
Research Centre, University of Cambridge, Cambridge, UK, 7Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, 
NC, USA, 8Department of Clinical and Population Science, Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, 
University of Leeds, Leeds, UK, 9Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA, 10Department of Molecular 
Medicine and Surgery, Upper Gastrointestinal Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 11School of 
Cancer and Pharmaceutical Sciences, King's College London, London, UK, 12Princess Margaret Cancer Center, Toronto, ON, Canada, 13Divisions of 
Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 14Chronic Disease Epidemiology, Yale 
School of Public Health, New Haven, CT, USA, 15Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel 
Hill, NC, USA, 16Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 17USC 
Norris Comprehensive Cancer Center,, University of Southern California, Los Angeles, CA, USA, 18Department of Preventive Medicine, Keck 
School of Medicine, University of Southern California, Los Angeles, CA, USA, 19Department of Medical Epidemiology and Biostatistics, Karolinska 
Institutet, Stockholm, Sweden 
 
ECAC 
Frederic Amant1, Daniela Annibali1, Katie Ashton2,3,4, John Attia2,5, Paul L. Auer6,7, Matthias W. 
Beckmann8, Amanda Black9, Louise Brinton9, Daniel D. Buchanan10,11,12,13, Stephen J. Chanock9, Chu 
Chen14, Maxine M. Chen15, Timothy H.T. Cheng16, Linda S. Cook17,18, Marta Crous-Bous19,15, Kamila 
Czene20, Jeroen Depreeuw1,21,22, Jennifer Anne Doherty23, Thilo Dörk24, Sean C. Dowdy25, Alison M. 
Dunning26, Matthias Dürst27, Douglas F. Easton26,28, Arif B. Ekici29, Peter A. Fasching30,8, Brooke L. 
Fridley31, Christine M. Friedenreich18, Montserrat García-Closas9,32, Mia M. Gaudet33, Graham G. 
Giles34,11,35, Dylan M. Glubb36, Ellen L. Goode37, Maggie Gorman16, Christopher A. Haiman38, Per 
Hall20,39, Susan E. Hankinson19,40, Catherine S. Healey26, Alexander Hein8, Peter Hillemanns24, Shirley 
Hodgson41, Erling Hoivik42,43, Elizabeth G. Holliday2,5, David J. Hunter44,15,45, Angela Jones16, Peter 
Kraft44,15, Camilla Krakstad43,42, Diether Lambrechts46,22, Loic Le Marchand47, Xiaolin Liang48, Annika 
Lindblom49,50, Jolanta Lissowska51, Jirong Long52, Lingeng Lu53, Anthony M. Magliocco54, Lynn 
Martin55, Mark McEvoy5, Roger L. Milne34,11,35, Miriam Mints56, Rami Nassir57, Irene Orlow48, Geoffrey 
Otton58, Claire Palles16, Paul DP. Pharoah26,28, Loreall Pooler38, Tony Proietto58, Timothy R. 
Rebbeck59,60, Stefan P. Renner8, Harvey A. Risch53, Matthias Rübner8, Ingo Runnebaum27, Carlotta 
Sacerdote61,62, Gloria E. Sarto63, Fredrick Schumacher64, Rodney J. Scott65,4,2, V. Wendy Setiawan38, Mitul 
 39 
Shah26, Xin Sheng38, Xiao-Ou Shu52, Melissa C. Southey35,10, Emma Tham49,66, Jone Trovik42,43, Constance 
Turman15, David Van Den Berg38, Adriaan Vanderstichele67, Zhaoming Wang9, Penelope M. 
Webb68, Nicolas Wentzensen9, Henrica MJ. Werner42,43, Stacey J. Winham69, Lucy Xia38, Yong-Bing 
Xiang70, Hannah P. Yang9, Herbert Yu47, Wei Zheng52 
 
1Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals KU Leuven, University of Leuven, Leuven, 
Belgium, 2Hunter Medical Research Institute, John Hunter Hospital, Newcastle, New South Wales, Australia, 3Centre for Information Based 
Medicine, University of Newcastle, Callaghan, New South Wales, Australia, 4Discipline of Medical Genetics, School of Biomedical Sciences and 
Pharmacy, Faculty of Health, University of Newcastle, Callaghan, New South Wales, Australia, 5Centre for Clinical Epidemiology and Biostatistics, 
School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia, 6Cancer Prevention Program, Fred 
Hutchinson Cancer Research Center, Seattle, WA, USA, 7Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI, 
USA, 8Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-
University Erlangen-Nuremberg, Erlangen, Germany, 9Division of Cancer Epidemiology and Genetics, National Cancer Institute, National 
Institutes of Health, Rockville, MD, USA, 10Department of Clinical Pathology, The University of Melbourne, Melbourne, Victoria, 
Australia, 11Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, 
Melbourne, Victoria, Australia, 12Genetic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, Victoria, Australia, 13University 
of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, Victoria, Australia, 14Epidemiology Program, Fred 
Hutchinson Cancer Research Center, Seattle, WA, USA, 15Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 
USA, 16Wellcome Trust Centre for Human Genetics and Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK, 17University 
of New Mexico Health Sciences Center, University of New Mexico, Albuquerque, NM, USA, 18Department of Cancer Epidemiology and 
Prevention Research, Alberta Health Services, Calgary, AB, Canada, 19Department of Medicine, Channing Division of Network Medicine, Brigham 
and Women's Hospital and Harvard Medical School, Boston, MA, USA, 20Department of Medical Epidemiology and Biostatistics, Karolinska 
Institutet, Stockholm, Sweden, 21Vesalius Research Center, VIB, Leuven, Belgium, 22Department of Human Genetics, Laboratory for Translational 
Genetics, University of Leuven, Leuven, Belgium, 23Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, 
Salt Lake City, UT, USA, 24Gynaecology Research Unit, Hannover Medical School, Hannover, Germany, 25Department of Obstetrics and 
Gynecology, Division of Gynecologic Oncology, Mayo Clinic, Rochester, MN, USA, 26Department of Oncology, Centre for Cancer Genetic 
Epidemiology, University of Cambridge, Cambridge, UK, 27Department of Gynaecology, Jena University Hospital - Friedrich Schiller University, 
Jena, Germany, 28Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, 
UK, 29Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer 
Center Erlangen-EMN, Erlangen, Germany, 30Department of Medicine Division of Hematology and Oncology, David Geffen School of Medicine, 
University of California at Los Angeles, Los Angeles, CA, USA, 31Department of Biostatistics, Kansas University Medical Center, Kansas City, KS, 
USA, 32Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK, 33Behavioral and Epidemiology Research Group, 
American Cancer Society, Atlanta, GA, USA, 34Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia, 35Precision 
Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia, 36Department of Genetics and 
Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia, 37Department of Health Science Research, 
Division of Epidemiology, Mayo Clinic, Rochester, MN, USA, 38Department of Preventive Medicine, Keck School of Medicine, University of 
Southern California, Los Angeles, CA, USA, 39Department of Oncology, Södersjukhuset, Stockholm, Sweden, 40Department of Biostatistics & 
Epidemiology, University of Massachusetts, Amherst, Amherst, MA, USA, 41Department of Clinical Genetics, St George's, University of London, 
London, UK, 42Department of Clinical Science, Centre for Cancerbiomarkers, University of Bergen, Bergen, Norway, 43Department of Gynecology 
and Obstetrics, Haukeland University Hospital, Bergen, Norway, 44Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan 
School of Public Health, Boston, MA, USA, 45Nuffield Department of Population Health, University of Oxford, Oxford, UK, 46VIB Center for Cancer 
Biology, VIB, Leuven, Belgium, 47Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA, 48Department of Epidemiology 
and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, 49Department of Molecular Medicine and Surgery, Karolinska 
Institutet, Stockholm, Sweden, 50Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden, 51Department of Cancer 
Epidemiology and Prevention, M. Sklodowska-Curie Cancer Center, Oncology Institute, Warsaw, Poland, 52Department of Medicine, Vanderbilt 
Epidemiology Center, Vanderbilt-Ingram Cancer Center, Division of Epidemiology, Vanderbilt University School of Medicine, Nashville, TN, 
USA, 53Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA, 54Department of Anatomic Pathology, Moffitt Cancer 
Center & Research Institute, Tampa, FL, USA, 55Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, 
UK, 56Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden, 57Department of Biochemistry and Molecular 
Medicine, University of California Davis, Davis, CA, USA, 58School of Medicine and Public Health, University of Newcastle, Callaghan, New South 
Wales, Australia, 59Harvard T.H. Chan School of Public Health, Boston, MA, USA, 60Dana-Farber Cancer Institute, Boston, MA, USA, 61Center for 
Cancer Prevention (CPO-Peimonte), Turin, Italy, 62Human Genetics Foundation (HuGeF), Turino, Italy, 63Department of Obstetrics and 
Gynecology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA, 64Department of Population and Quantitative 
Health Sciences, Case Western Reserve University, Cleveland, OH, USA, 65Pathology North, Division of Molecular Medicine, John Hunter 
Hospital, Newcastle, New South Wales, Australia, 66Clinical Genetics, Karolinska Institutet, Stockholm, Sweden, 67Department of Obstetrics and 
Gynaecology and Leuven Cancer Institute, Division of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium, 68Population Health 
Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia, 69Department of Health Science Research, Division 
of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA, 70State Key Laboratory of Oncogene and Related Genes & 
Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China 
 
GECCO, CORECT, CCFR 
Goncalo R. Abecasis1, Yoon-Ok Ahn2, Barbara Banbury3, John A. Baron4, Sonja I. Berndt5, Stéphane 
Bézieau6, Stephanie A. Bien3, Hermann Brenner7,8,9, Daniel D. Buchanan10,11,12, Qiuyin Cai13, Andrew T. 
 40 
Chan14,15,16, Jenny Chang-Claude17,18, David V. Conti19, Keith R. Curtis3, Christopher K. Edlund19, Dallas R. 
English20,21, Jane Figueiredo22, Steven J. Gallinger23, Graham G. Giles21,20, Robert W. Haile24, Tabitha A. 
Harrison3, John L. Hopper20,25, Thomas J. Hudson26, David J. Hunter27,28, Jeroen R. Huyghe3, Jae Hwan 
Oh2, Sun Ha Jee29, Wei-Hua Jia30, Amit D. Joshi27,16, Keum Ji Jung31, Yoichiro Kamatani32, Dong-Hyun 
Kim33, Jeongseon Kim34, Charles Kooperberg3, Sébastien Küry6, Sun-Seog Kweon2,35, Loic Le 
Marchand36, Mathieu Lemire37, Li Li38, Yi Lin3, Noralane M. Lindor39, Jirong Long13, Yingchang Lu13, Koichi 
Matsuda40, Keitaro Matsuo41,42, Roger L. Milne21,20, Polly A. Newcomb3,43, Deborah A. Nickerson44, Shuji 
Ogino45,46,27, Isao Oze41, John D. Potter3, Conghui Qu3, Gad Rennert47,48,49, Hedy S. Rennert47,48,49, Lori C. 
Sakoda50,3, Robert E. Schoen51, Fredrick R. Schumacher52, Min-Ho Shin2, Aesun Shin53, Xiao-Ou 
Shu54, Martha L. Slattery55, Melissa C. Southey56, Stephen N. Thibodeau57, Emily White3,58, Michael O. 
Woods59, Yong-Bing Xiang60, Brent W. Zanke61, Yi-Xin Zeng30 
 
1Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, USA, 2Department of Preventive 
Medicine, Seoul National University College of Medicine, Seoul, South Korea, 3Public Health Sciences Division, Fred Hutchinson Cancer Research 
Center, Seattle, WA, USA, 4Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA, 5Division of Cancer 
Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA, 6Service de Génétique Médicale, Centre 
Hospitalier Universitaire (CHU) Nantes France, Nantes, France, 7Division of Clinical Epidemiology and Aging Research, German Cancer Research 
Center (DKFZ), Heidelberg, Germany, 8Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor 
Diseases (NCT), Heidelberg, Germany, 9German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, 
Germany, 10Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, 
Australia, 11University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, Victoria, 
Australia, 12Genetic Medicine and Family Cancer Clinic, The Royal Melbourne Hospital, Parkville, Victoria, Australia, 13Division of Epidemiology, 
Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, 
Nashville, TN, USA, 14Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, 15Channing 
Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, 16Clinical and Translational 
Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, 17Division of Cancer Epidemiology, German 
Cancer Research Center (DKFZ), Heidelberg, Germany, 18University Medical Centre Hamburg-Eppendorf, University Cancer Centre Hamburg 
(UCCH), Hamburg, Germany, 19Department of Preventive Medicine, USC Norris Comprehensive Cancer Center, Keck School of Medicine, 
University of Southern California, Los Angeles, CA, USA, 20Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global 
Health, The University of Melbourne, Melbourne, Victoria, Australia, 21Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, 
Victoria, Australia, 22Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA, 23Lunenfeld 
Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada, 24Department of Medicine, Division of 
Oncology, Stanford University, Stanford, CA, USA, 25Department of Epidemiology, School of Public Health and Institute of Health and 
Environment, Seoul National University, Seoul, South Korea, 26Ontario Institute for Cancer Research, Toronto, Ontario, Canada, 27Department of 
Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA, 28Nuffield Department of Population Health, 
University of Oxford, Oxford, UK, 29Department of Epidemiology and Health Promotion, Graduate School of Public Health, Yonsei University, 
Seoul, South Korea, 30State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, Guangzhou, China, 31Institute for 
Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, South Korea, 32Laboratory for Statistical Analysis, RIKEN Center 
for Integrative Medical Sciences, Kanagawa, Japan, 33Department of Social and Preventive Medicine, Hallym University College of Medicine, 
Okcheon-dong, South Korea, 34Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer 
Center, Gyeonggi-do, South Korea, 35Jeonnam Regional Cancer Center, Chonnam National University Hwasun Hospital, Hwasun, South 
Korea, 36University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, USA, 37PanCuRx Translational Research Initiative, Ontario 
Institute for Cancer Research, Toronto, Ontario, Canada, 38Department of Family Medicine, University of Virginia, Charlottesville, VA, 
USA, 39Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, AZ, USA, 40Laboratory of Clinical Genome Sequencing, 
Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, University of Tokyo, Tokyp, Japan, 41Division 
of Molecular and Clinical Epidemiology, Aichi Cancer Center Research Institute, Nagoya, Japan, 42Department of Epidemiology, Nagoya 
University Graduate School of Medicine, Nagoya, Japan, 43School of Public Health, University of Washington, Seattle, WA, USA, 44Department of 
Genome Sciences, University of Washington, Seattle, WA, USA, 45Program in MPE Molecular Pathological Epidemiology, Department of 
Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, 46Department of Oncologic Pathology, Dana-Farber 
Cancer Institute, Boston, MA, USA, 47Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa, 
Israel, 48Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, 49Clalit National Cancer Control 
Center, Haifa, Israel, 50Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA, 51Department of Medicine and 
Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA, 52Department of Population and Quantitative Health Sciences, Case 
Western Reserve University, Cleveland, OH, USA, 53Department of Preventive Medicine, Seoul National University College of Medicine, Seoul 
National University Cancer Research Institute, Seoul, South Korea, 54Vanderbilt University Medical Center, Nashville, TN, USA, 55Department of 
Internal Medicine, University of Utah, Salt Lake City, Utah, USA, 56Genetic Epidemiology Laboratory, Department of Pathology, The University of 
Melbourne, Melbourne, Australia, 57Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, 
Rochester, MN, USA, 58Department of Epidemiology, University of Washington School of Public Health, Seattle, WA, USA, 59Memorial University 
of Newfoundland, Discipline of Genetics, St. John's, Canada, 60State Key Laboratory of Oncogenes and Related Genes & Department of 
Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, 61University of 




Lars A. Akslen1, Christopher I. Amos2, Per A. Andresen3, Marie-Françoise Avril4, Esther Azizi5, Jennifer H. 
Barrett6, Giovanna Bianchi Scarrà7, Myriam Brossard8,9, Kevin M. Brown10, Kathryn P. Burdon11, Wei V. 
Chen12, Jamie E. Craig13, Anne E. Cust14, Tadeusz Dębniak15, David L. Duffy16, Alison M. 
Dunning17, Douglas F. Easton17,18, David E. Elder19, Shenying Fang20, Eitan Friedman21, Pilar Galan22, Paola 
Ghiorzo7, Elizabeth M. Gillanders23, Alisa M. Goldstein10, Nelleke A. Gruis24, Jiali Han25, Johan 
Hansson26, Mark Harland27, Nicholas K. Hayward28, Per Helsing29, Marko Hočevar30, Veronica 
Höiom26, Christian Ingvar31, Peter A. Kanetsky32, Rajiv Kumar33, Katerina P. Kypreou34, Maria Teresa 
Landi10, Julie Lang35, G. Mark Lathrop36, Jeffrey E. Lee20, Jan Lubiński15, Rona M. Mackie37, Graham J. 
Mann38, Nicholas G. Martin16, Anders Molven39, Grant W. Montgomery40, Eric K. Moses41, Julia A. 
Newton Bishop27, Srdjan Novaković42, Dale R. Nyholt43, Håkan Olsson44, Nick Orr45, Paul D.P. 
Pharoah17, Karen A. Pooley18, Susana Puig46, Joan Anton Puig Butille46, Abrar A. Qureshi47, Graham L. 
Radford-Smith48, Juliette Randerson-Moor27, Dirk Schadendorf49, Hans-Joachim Schulze50, Lisa A. 
Simms48, Fengju Song51, Alexander J. Stratigos34, Anthony J. Swerdlow52, John C. Taylor6, Nienke van der 
Stoep53, Remco van Doorn24, David C. Whiteman54 
 
1Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway, 2Department of Medicine, Baylor 
College of Medicine, Houston, TX, USA, 3Department of Pathology, Molecular Pathology, Oslo University Hospital, Rikshospitalet, Oslo, 
Norway, 4Assistance Publique–Hôpitaux de Paris, Hôpital Cochin, Service de Dermatologie, Université Paris Descartes, Paris, 
France, 5Department of Dermatology, Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv, Israel, 6Division of Pathology 
and Data Analytics, Leeds Institute of Medical Research, University of Leeds, Leeds, UK, 7Department of Internal Medicine and Medical 
Specialties, University of Genoa, Genoa, Italy, 8Université de Paris, INSERM, UMR-1124, Paris, France, 9Division of Biotstatistics, Lunenfeld 
Tanenbaum Research Institute, Toronto, Canada, 10Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes 
of Health, Rockville, MD, USA, 11Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia, 12Department of 
Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 13Department of Ophthalmology, Flinders University, 
Adelaide, Australia, 14Cancer Epidemiology and Services Research, Sydney School of Public Health, University of Sydney, Sydney, New South 
Wales, Australia, 15International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland, 16Genetic Epidemiology, QIMR 
Berghofer Medical Research Institute, Brisbane, Australia, 17Centre for Cancer Genetic Epidemiology, Department of Oncology, University of 
Cambridge, Cambridge, UK, 18Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 
Cambridge, UK, 19Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, 
Philadelphia, PA, USA, 20Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 
USA, 21Oncogenetics Unit, Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv, Israel, 22Université Paris 13, Equipe de 
Recherche en Epidémiologie Nutritionnelle (EREN), Centre de Recherche en Epidémiologie et Biostatistiques de Sorbonne Paris Cité (CRESS), 
Institut National de la Santé et de la Recherche Médicale (INSERM U1153), Institut National de la Recherche Agronomique (INRA U1125), 
Conservatoire National des Arts et Métiers, Bobigny, France, 23Inherited Disease Research Branch, National Human Genome Research Institute, 
National Institutes of Health, Baltimore, MD, USA, 24Department of Dermatology, Leiden University Medical Centre, Leiden, The 
Netherlands, 25Department of Epidemiology, Richard M. Fairbanks School of Public Health, Melvin and Bren Simon Cancer Center, Indiana 
University, Indianapolis, IN, USA, 26Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, 
Sweden, 27Division of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK, 28Oncogenomics, 
QIMR Berghofer Medical Research Institute, Brisbane, Australia, 29Department of Dermatology, Oslo University Hospital, Rikshospitalet, Oslo, 
Norway, 30Department of Surgical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia, 31Department of Surgery, Clinical Sciences, 
Lund University, Lund, Sweden, 32Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 
USA, 33Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany, 34Department of Dermatology, 
University of Athens School of Medicine, Andreas Sygros Hospital, Athens, Greece, 35Department of Medical Genetics, University of Glasgow, 
Glasgow, UK, 36McGill University, Montreal, Canada, 37Department of Public Health, University of Glasgow, Glasgow, UK, 38Centre for Cancer 
Research, University of Sydney at Westmead, Millennium Institute for Medical Research and Melanoma Institute Australia, Sydney, 
Australia, 39Department of Pathology, Haukeland University Hospital, Bergen, Norway, 40Molecular Biology, The University of Queensland, 
Brisbane, Australia, 41Centre for Genetic Origins of Health and Disease, Faculty of Medicine, Dentistry and Health Sciences, The University of 
Western Australia, Perth, Western Australia, Australia, 42Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Ljubljana, 
Slovenia, 43Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia, 44Department 
of Oncology/Pathology, Clinical Sciences, Lund University, Lund, Sweden, 45Centre for Cancer Research and Cell Biology, Queen's University 
Belfast, Belfast, UK, 46Melanoma Unit, Dermatology Department & Biochemistry and Molecular Genetics Departments, Hospital Clinic, Institut 
de Investigacó Biomèdica August Pi Suñe, Barcelona, Spain, 47Department of Dermatology, The Warren Alpert Medical School of Brown 
University, Providence, RI, USA, 48Inflammatory Bowel Diseases, QIMR Berghofer Medical Research Institute, Brisbane, Australia, 49Department 
of Dermatology, University Hospital Essen, Essen, Germany, 50Department of Dermatology, Fachklinik Hornheide, Institute for Tumors of the 
Skin at the University of Münster, Münster, Germany, 51Departments of Epidemiology and Biostatistics, Key Laboratory of Cancer Prevention 
and Therapy, National Clinical Research Center of Cancer, Tianjin, P.R. China, 52Division of Genetics and Epidemiology, The Institute of Cancer 
 42 
Research, London, UK, 53Department of Clinical Genetics, Center of Human and Clinical Genetics, Leiden University Medical Centre, Leiden, The 
Netherlands, 54Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia 
 
GICC 
Francis Ali-Osman1, Christopher I. Amos2, Georgina Armstrong2, Jonine Bernstein3, Elizabeth Claus4, Dora 
Il'yasova5, Robert Jenkins6, Christoffer Johansen7, Daniel Lachance8, Rose Lai9, Ryan Merrell10, Sara 
Olson3, Quinn Ostrom2, Siegal Sadetzki11, Michael Scheurer12, Joellen Schildkraut13, Sanjay Shete14 
 
1Department of Surgery, Duke University Medical Center, Durham, NC, USA, 2Department of Medicine, Section of Epidemiology and Population 
Sciences, Baylor College of Medicine, Houston, TX, USA, 3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer 
Center, New York, NY, USA, 4Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA, 
5Department of Epidemiology and Biostatistics, Georgia State University School of Public Health, Atlanta, GA, USA, 6Department of Laboratory 
Medicine and Pathology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA, 7Rigshospitalet and Survivorship Research Unit, The 
Danish Cancer Society Research Center, Copenhagen, Denmark, 8Department of Neurology, Mayo Clinic Comprehensive Cancer Center, 
Rochester, MN, USA, 9Departments of Neurology and Preventive Medicine, University of Southern California, Keck School of Medicine, Los 
Angeles, CA, USA, 10Department of Neurology, NorthShore University Health System, Evanston, IL, USA, 11Cancer and Radiation Epidemiology 
Unit, Gertner Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel, 12Department of Pediatrics, Baylor College of Medicine, Houston, TX, 
USA, 13Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA, USA, 14Department of Biostatistics, 
University of Texas MD Anderson Cancer Center, Houston, TX, USA 
 
ILCCO/Integral 
Demetrios Albanes1, Melinda C. Aldrich2, Christopher I. Amos3, Angeline S. Andrew4, Susanne M. Arnold5, 
Heike Bickeböller6, Stig E. Bojesen7,8,9, Paul Brennan10, Hans Brunnström11, Neil Caporaso1, Chu Chen12, 
David C. Christiani13, John K. Field14, Kjell Grankvist15, Rayjean J. Hung16, Mattias Johansson10, Mikael 
Johansson17, Lambertus A. Kiemeney18, Stephen Lam19, Maria Teresa Landi1, Philip Lazarus20, Geoffrey 
Liu21, Loic Le Marchand22, Olle Melander23,24, Gadi Rennert25, Angela Risch26,27,28, Matthew B. Schabath29, 
Hongbing Shen30, Sanjay S. Shete31, Adonina Tardon32, M. Dawn Teare33, H-Erich Wichmann34,35,36, Shan 
Zienolddiny37 
 
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA, 2Department of Thoracic Surgery, Division of 
Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA, 3Institute for Clinical and Translational Research, Dan L. Duncan 
Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA, 4Norris Cotton Cancer Center, Dartmouth Geisel School of 
Medicine, Lebanon, NH, USA, 5Markey Cancer Center, University of Kentucky, Lexington, KY, USA, 6University Medical Center Goettingen, 
Goettingen, Germany, 7Copenhagen General Population Study, Herlev and Gentofte Hospital, Herlev, Denmark, 8Department of Clinical 
Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark, 9Faculty of Health and Medical Sciences, 
University of Copenhagen, Copenhagen, Denmark, 10International Agency for Research on Cancer, Lyon, France, 11Pathology, Department of 
Clinical Sciences Lund, Laboratory Medicine Region Skåne, Lund University, Lund, Sweden, 12Public Health Sciences Division, Fred Hutchinson 
Cancer Research Center, Seattle, WA, USA, 13Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA, 
14Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK, 15Department of Medical Biosciences, Umeå 
University, Umeå, Sweden, 16Lunenfeld-Tanenbuaum Research Institute, Sinai Health System, Toronto, ON, Canada, 17Department of Radiation 
Sciences, Umeå University, Umeå, Sweden, 18Radboud University Medical Center, Nijmegen, The Netherlands, 19British Columbia Cancer 
Agency, Vancouver, BC, Canada, 20College of Pharmacy, Washington State University, Spokane, WA, USA, 21Princess Margaret Cancer Center, 
Toronto, ON, Canada, 22Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA, 23Department of Clinical Sciences Malmö, 
Lund University, Lund, Sweden, 24Department of Internal Medicine, Skåne University Hospital, Malmö, Sweden, 25Carmel Medical Center and 
Technion Faculty of Medicine, Haifa, Israel, 26University of Salzburg and Cancer Cluster, Salzburg, Germany, 27Translational Lung Research 
Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany, 28German Cancer Research Center (DKFZ), 
Heidelberg, Germany, 29Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, 
30Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation 
Center for Cancer Personalized Medicine, School of Public Health, Nanjing, P.R. China, 31Department of Epidemiology, The University of Texas 
MD Anderson Cancer Center, Houston, TX, USA, 32Faculty of Medicine, IUOPA, University of Oviedo and CIBERESP, Oviedo, Spain, 33School of 
Health and Related Research (ScHARR), University Of Sheffield, Sheffield, UK, 34Institute of Medical Informatics, Biometry and Epidemiology, 
Chair of Epidemiology, Ludwig Maximilians University, Munich, Germany, 35Helmholtz Center Munich, Institute of Epidemiology, Neuherberg, 
Germany, 36Institute of Medical Statistics and Epidemiology, Technical University Munich, Munich, Germany, 37National Institute of 
Occupational Health (STAMI), Oslo, Norway 
 
InterLymph 
Demetrius Albanes1, Yolanda Benavente2,3, Paige M. Bracci4, Angela R. Brooks-Wilson5,6, Neil E. 
Caporaso1, James Cerhan7, Jacqueline Clavel8,9, Pierluigi Cocco10, Silvia de Sanjose2,3, Graham G. 
 43 
Giles11,12, Henrik Hjalgrim13, Rebecca D. Jackson14, Eleanor Kane15, Qing Lan1, Brian K. Link16, Alain 
Monnereau8,9, Alexandra Nieters17, Kari E. North18,19, Kenneth Offit20, Elio Riboli21, Christine F. 
Skibola22, Karin E. Smedby23,24, John J. Spinelli25,26, Lauren R. Teras27, Lesley F. Tinker28, Claire M. 
Vajdic29, Roel C.H. Vermeulen30,31, Joseph Vijai20, Paolo Vineis32,33, Anne Zeleniuch-Jacquotte34,35,36, Yawei 
Zhang37 
 
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA, 2Cancer 
Epidemiology Research Programme, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain, 3CIBER de Epidemiología 
y Salud Pública (CIBERESP), Barcelona, Spain, 4Department of Epidemiology and Biostatistics, University of California San Francisco, San 
Francisco, CA, USA, 5Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada, 6Department of Biomedical Physiology 
and Kinesiology, Simon Frazer University, Burnaby, British Columbia, Canada, 7Department of Internal Medicine, Mayo Clinic, Rochester, MN, 
USA, 8Epidemiology of Childhood and Adolescent Cancers Group, Inserm, Center of Research in Epidemiology and Statistics Sorbonne Paris Cité 
(CRESS), Paris, France, 9Université Paris Descartes, Paris, France, 10Department of Public Health, Clinical and Molecular Medicine, University of 
Cagliari, Monserrato, Cagliari, Italy, 11Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, Victoria, 
Australia, 12Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health,, University of Melbourne, Melbourne, 
Victoria, Australia, 13Department of Epidemiology Research, Division of Health Surveillance and Research, Statens Serum Institut, Copenhagen, 
Denmark, 14Division of Endocrinology, Diabetes and Metabolism, The Ohio State University, Columbus, OH, USA, 15Department of Health 
Sciences, University of York, York, UK, 16Department of Internal Medicine, Carver College of Medicine, The University of Iowa, Iowa City, IA, 
USA, 17Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Baden-Württemberg, Germany, 18Department of 
Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 19Carolina Center for Genome Sciences, University of North 
Carolina at Chapel Hill, Chapel Hill, NC, USA, 20Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, 21School 
of Public Health, Imperial College London, London, UK, 22Department of Hematology and Medical Oncology, Emory University School of 
Medicine, Atlanta, GA, USA, 23Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 24Hematology Center, Karolinska 
University Hospital, Stockholm, Sweden, 25Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada, 26School of 
Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada, 27Epidemiology Research Program, American 
Cancer Society, Atlanta, GA, USA, 28Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 29Centre for 
Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia, 30Institute for Risk Assessment Sciences, 
Utrecht University, Utrecht, The Netherlands, 31Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, 
The Netherlands, 32MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, UK, 33Human 
Genetics Foundation, Turin, Italy, 34Department of Population Health, New York University School of Medicine, New York, NY, 
USA, 35Department of Environmental Medicine, New York University School of Medicine, New York, NY, USA, 36Perlmutter Cancer Center, NYU 
Langone Medical Center, New York, NY, USA, 37Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT, USA 
 
OCAC 
Katja K.H. Aben1,2, AOCS Group3,4, Hoda Anton-Culver5, Natalia N. Antonenkova6, Gerassimos 
Aravantinos7, Susana N. Banerjee8, Yukie Bean9, Matthias W. Beckmann10, Alicia Beeghly-Fadiel11, Javier 
Benitez12,13, Marina Bermisheva14, Marcus Q. Bernardini15, Line Bjorge16,17, Amanda Black18, Clara 
Bodelon18, Natalia V. Bogdanova19,20,6, James D. Brenton21, Louise Brinton18, Per Broberg22, Angela 
Brooks-Wilson23,24, Fiona Bruinsma25, Ralf Butzow26, Ian Campbell27,28, Rikki Cannioto29, Michael E. 
Carney30, Jenny Chang-Claude31,32, Stephen J. Chanock18, Xiao Qing Chen4, Georgia Chenevix-
Trench4, Yoke-Eng Chiew33,34, Linda S. Cook35, Daniel W. Cramer36,37, Julie M. Cunningham38, Aimee A. 
D'Aloisio39, Agnieszka Dansonka-Mieszkowska40, Fanny Dao41, Anna deFazio33,34, Joe Dennis42, Ed 
Dicks43, Jennifer Anne Doherty44, Thilo Dörk20, Laure Dossus45, Matthias Dürst46, Diana M. Eccles47, Todd 
Edwards48, Arif B. Ekici49, Ailith Ewing42, Peter A. Fasching50,10, Sarah Ferguson51, James M. 
Flanagan52, Zachary C. Fogarty53, Renée T. Fortner31, Florentia Fostira54, George Fountzilas55, María J. 
García56,57, Aleksandra Gentry-Maharaj58, Graham G. Giles59,60,61, Rosalind Glasspool62, Marc T. 
Goodman63, Teodora Goranova21, Jacek Gronwald64, OPAL Study Group65, Christopher A. 
Haiman66, Niclas Håkansson67, Holly R. Harris68,69, Dennis Hazelett70, Alexander Hein10, Michelle A.T. 
Hildebrandt71, Peter Hillemanns20, Claus K. Høgdall72, Estrid Høgdall73,74, Helene Holland4, Karen 
Hosking75, Ruea-Yea Huang76, David G. Huntsman77,78,79,80, Tomasz Huzarski64, Liher Imaz81,82, Anna 
Jakubowska64,83, Allan Jensen73, Sharon Johnatty4, Michael E. Jones84, Pääivy Kannistö85, Siddhartha 
Kar43, Beth Y. Karlan86,87, Anthony Karnezis88, Linda E. Kelemen89, Catherine J. Kennedy33,34, Elza 
Khusnutdinova90,14, Lambertus A. Kiemeney1, Susanne K. Kjaer73,91, Martin Köbel92, Reidun K. 
Kopperud16,17, Jolanta Kupryjanczyk40, Diether Lambrechts93,94, Melissa C. Larson53, Kate 
Lawrenson95, Nhu D. Le96, Loic Le Marchand97, Shashikant B. Lele98, Jenny Lester86,87, Douglas A. 
 44 
Levine41,99, Dong Liang100, Clemens Liebrich101, Loren Lipworth102, Jolanta Lissowska103, Karen H. Lu104, Jan 
Lubiński64, Lene Lundvall72, Leon F.A.G. Massuger105, Taymaa May106, Jessica McAlpine107, Valerie 
McGuire108, John R. McLaughlin109, Iain A. McNeish110,111, Usha Menon58, Melissa 
Merritt112,113, Francesmary Modugno114,115, Melissa Moffitt9,116, Alvaro N. Monteiro117, Steven A. 
Narod118, Lotte Nedergaard119, Roberta B. Ness120, Heli Nevanlinna121, Kunle Odunsi98, Siel 
Olbrecht122, Håkan Olsson22, N. Charlotte Onland-Moret123, Nick Orr124, Sandra Orsulic87, Ana 
Osorio12,56, Domenico Palli125, Sue K. Park126,127,128, Tjoung-Won Park-Simon20, James Paul129, Tanja 
Pejovic9,116, Liisa M. Pelttari130, Jennifer B. Permuth117, Malcolm C. Pike131,132, Anna Piskorz21, Joanna 
Plisiecka-Halasa40, Darya Prokofyeva90, Susan J. Ramus133,134, Marjorie J. Riggan135, Cristina Rodriguez-
Antona13,57, Mary Anne Rossing68,69, Joseph H. Rothstein136,137, Ingo Runnebaum46, Dale P. 
Sandler138, Minouk J. Schoemaker84, V. Wendy Setiawan139, Gianluca Severi140,141,142,143, Nadeem 
Siddiqui144, Weiva Sieh137,136, Honglin Song43, Melissa C. Southey61,145, Lara Sucheston146, Rebecca 
Sutphen147, Anthony J. Swerdlow84,148, Lukasz Szafron149, Jack A. Taylor138,150, Soo H. Teo151,152, Kathryn L. 
Terry36,37, Liv Cecilie Vestrheim Thomsen16,17, Anne Tinker153, Linda Titus154, Alicia Tone106, Britton 
Trabert18, Ruth Travis155, Antonia Trichopoulou156,157, Jonathan P. Tyrer43, Shelley S. Tworoger117,36, Anne 
M. van Altena158, David Van Den Berg139, Els Van Nieuwenhuysen122, Digna R. Velez Edwards159, Ignace 
Vergote122, Robert A. Vierkant53, Christine Walsh87, Shan Wang-Gohrke160, Penelope M. Webb65, Clarice 
R. Weinberg161, Nicolas Wentzensen18, Alice S. Whittemore108,162, Lynne R. Wilkens163, Stacey J. 
Winham53, Alicja Wolk67,164, Michelle Woo165, Xifeng Wu71, Anna H. Wu139, Hannah P. Yang18, Drakoulis 
Yannoukakos54, Argyrios Ziogas5 
 
1Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands, 2Netherlands Comprehensive Cancer 
Organisation, Utrecht, The Netherlands, 3Research Department, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia, 4Department 
of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia, 5Department of 
Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA, 6N.N. Alexandrov Research Institute of 
Oncology and Medical Radiology, Minsk, Belarus, 7"Agii Anargiri" Cancer Hospital, Athens, Greece, 8Gynaecology Unit, Royal Marsden Hospital, 
London, UK, 9Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, USA, 10Department of Gynecology 
and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, 
Erlangen, Germany, 11Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Division of Epidemiology, 
Vanderbilt University School of Medicine, Nashville, TN, USA, 12Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, 
Spain, 13Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain, 14Institute of Biochemistry and 
Genetics, Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, Russia, 15University Health Network, Division of Gynecologic 
Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada, 16Department of Obstetrics and Gynecology, Haukeland University Hospital, 
Bergen, Norway, 17Department of Clinical Science, Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway, 18Division of 
Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA, 19Department of Radiation 
Oncology, Hannover Medical School, Hannover, Germany, 20Gynaecology Research Unit, Hannover Medical School, Hannover, 
Germany, 21Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK, 22Department of Cancer Epidemiology, Clinical 
Sciences, Lund University, Lund, Sweden, 23Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada, 24Department of Biomedical 
Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada, 25Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, 
Victoria, Australia, 26Department of Pathology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, 27Research Department, 
Peter MacCallum Cancer Center, Melbourne, Victoria, Australia, 28Sir Peter MacCallum Department of Oncology, The University of Melbourne, 
Melbourne, Victoria, Australia, 29Cancer Pathology & Prevention, Division of Cancer Prevention and Population Sciences, Roswell Park Cancer 
Institute, Buffalo, NY, USA, 30Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, 
USA, 31Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, 32Cancer Epidemiology Group, 
University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 33Centre for Cancer Research, 
The Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia, 34Department of Gynaecological 
Oncology, Westmead Hospital, Sydney, New South Wales, Australia, 35University of New Mexico Health Sciences Center, University of New 
Mexico, Albuquerque, NM, USA, 36Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA, 37Obstetrics and 
Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, 38Department of Laboratory 
Medicine and Pathology, Mayo Clinic, Rochester, MN, USA, 39Social & Scientific Systems, Inc., Durham, NC, USA, 40Department of Pathology and 
Laboratory Medicine, Institute of Oncology and Maria Sklodowska-Curie Cancer Center, Warsaw, Poland, 41Department of Surgery, Gynecology 
Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA, 42Department of Public Health and Primary Care, Centre for Cancer 
Genetic Epidemiology, University of Cambridge, Cambridge, UK, 43Department of Oncology, Centre for Cancer Genetic Epidemiology, University 
of Cambridge, Cambridge, UK, 44Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 
USA, 45Nutrition and Metabolism Section, International Agency for Research on Cancer (IARC-WHO), Lyon, France, 46Department of 
Gynaecology, Jena University Hospital - Friedrich Schiller University, Jena, Germany, 47Faculty of Medicine, University of Southampton, 
Southampton, UK, 48Department of Medicine, Division of Epidemiology, Center for Human Genetics Research, Vanderbilt University Medical 
Center, Nashville, TN, USA, 49Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, 
 45 
Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany, 50Department of Medicine Division of Hematology and Oncology, David 
Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA, 51Division of Gynecologic Oncology, University Health 
Network, Princess Margaret Hospital, Toronto, Ontario, Canada, 52Department of Surgery and Cancer, Division of Cancer and Ovarian Cancer 
Action Research Centre, Imperial College London, London, UK, 53Department of Health Science Research, Division of Biomedical Statistics and 
Informatics, Mayo Clinic, Rochester, MN, USA, 54Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research 
"Demokritos", Athens, Greece, 55Second Department of Medical Oncology, EUROMEDICA General Clinic of Thessaloniki, Aristotle University of 
Thessaloniki School of Medicine, Thessalonıki, Greece, 56Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), 
Madrid, Spain, 57Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain, 58MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & 
Methodology, University College London, London, UK, 59Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, 
Australia, 60Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, 
Melbourne, Victoria, Australia, 61Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, 
Australia, 62Department of Medical Oncology, The Beatson West of Scotland Cancer Centre, Glasgow, UK, 63Samuel Oschin Comprehensive 
Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA, 64Department of Genetics and 
Pathology, Pomeranian Medical University, Szczecin, Poland, 65Population Health Department, QIMR Berghofer Medical Research Institute, 
Brisbane, Queensland, Australia, 66Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, 
CA, USA, 67Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 68Program in Epidemiology, Division of Public Health 
Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 69Department of Epidemiology, University of Washington, Seattle, WA, 
USA, 70Center for Bioinformatics and Functional Biology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los 
Angeles, CA, USA, 71Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA, 72Department of 
Gynecology, Rigshospitalet, The Juliane Marie Centre, University of Copenhagen, Copenhagen, Denmark, 73Department of Virus, Lifestyle and 
Genes, Danish Cancer Society Research Center, Copenhagen, Denmark, 74Molecular Unit, Department of Pathology, Herlev Hospital, University 
of Copenhagen, Copenhagen, Denmark, 75Department of Oncology, University of Cambridge, Cambridge, UK, 76Center For Immunotherapy, 
Roswell Park Cancer Institute, Buffalo, NY, USA, 77Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, 
Canada, 78Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, 79Department of 
Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada, 80British Columbia's Ovarian Cancer Research (OVCARE) 
Program, Vancouver General Hospital, University of British Columbia, BC Cancer and Vancouver General Hospital, Vancouver, BC, 
Canada, 81Biodonostia Health Research Institute, Donostia-San Sebastian, Spain, 82Ministry of Health of the Basque Government Public Health 
Division of Gipuzkoa, Donostia-San Sebastian, Spain, Public Health Division of Gipuzkoa, Donostia-San Sebastian, Spain, 83Independent 
Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland, 84Division of Genetics and 
Epidemiology, The Institute of Cancer Research, London, UK, 85Department of Gynecology, University Hospital, Lund, Sweden, 86Department of 
Obstetrics and Gynecology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA, 87Women's Cancer 
Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA, 88Department of Pathology 
and Laboratory Medicine, UC Davis Medical Center, Sacramento, CA, USA, 89Hollings Cancer Center, Medical University of South Carolina, 
Charleston, SC, USA, 90Department of Genetics and Fundamental Medicine, Bashkir State Medical University, Ufa, Russia, 91Department of 
Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 92Department of Pathology and Laboratory Medicine, 
University of Calgary, Foothills Medical Center, Calgary, AB, Canada, 93VIB Center for Cancer Biology, VIB, Leuven, Belgium, 94Laboratory for 
Translational Genetics, Department of Human Genetics, University of Leuven, Leuven, Belgium, 95Department of Obstetrics and Gynecology, 
Division of Gynecologic Oncology, Women’s Cancer Program at the Samuel Oschin Cancer Institute Cedars-Sinai Medical Center, Los Angeles, 
CA, USA, 96Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada, 97Epidemiology Program, University of Hawaii Cancer Center, 
Honolulu, HI, USA, 98Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA, 99Gynecologic Oncology, Laura and 
Isaac Pearlmutter Cancer Center, NYU Langone Medical Center, New York, NY, USA, 100College of Pharmacy and Health Sciences, Texas Southern 
University, Houston, TX, USA, 101Clinics of Gynaecology, Cancer Center Wolfsburg, Wolfsburg, Germany, 102Department of Medicine, Division of 
Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA, 103Department of Cancer Epidemiology and Prevention, M. Sklodowska-
Curie Cancer Center, Oncology Institute, Warsaw, Poland, 104Department of Gynecologic Oncology and Clinical Cancer Genetics Program, 
University of Texas MD Anderson Cancer Center, Houston, TX, USA, 105Department of Gynaecology, Radboud Institute for Molecular Life 
Sciences, Radboud University Medical Center, Nijmegen, The Netherlands, 106Division of Gynecologic Oncology, University Health Network, 
Princess Margaret Hospital, Toronto, Ontario, Canada, 107Department of Gynecology, Division Gynecologic Oncology, University of British 
Columbia and BC Cancer Agency, Vancouver, BC, Canada, 108Department of Health Research and Policy - Epidemiology, Stanford University 
School of Medicine, Stanford, CA, USA, 109Public Health Ontario, Samuel Lunenfeld Research Institute, Toronto, Ontario, Canada, 110Department 
Surgery & Cancer, Division of Cancer and Ovarian Cancer Action Research Centre, Imperial College London, London, UK, 111Institute of Cancer 
Sciences, University of Glasgow, Glasgow, UK, 112Department of Epidemiology and Biostatistics, School of Public Health, Imperial College 
London, London, UK, 113Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA, 114Womens Cancer Research Center, 
Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, PA, USA, 115Department of Obstetrics, Gynecology and Reproductive 
Sciences, Division of Gynecologic Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, 116Knight Cancer Institute, Oregon 
Health & Science University, Portland, OR, USA, 117Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA, 118Women's 
College Research Institute, University of Toronto, Toronto, Ontario, Canada, 119Department of Pathology, Rigshospitalet, University of 
Copenhagen, Copenhagen, Denmark, 120School of Public Health, University of Texas Health Science Center at Houston (UTHealth), Houston, TX, 
USA, 121Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, 122Department of 
Obstetrics and Gynaecology and Leuven Cancer Institute, Division of Gynecologic Oncology, University Hospitals Leuven, Leuven, 
Belgium, 123Julius Center for Health Sciences and Primary Care, University Utrecht, UMC Utrecht, Utrecht, The Netherlands, 124Centre for Cancer 
Research and Cell Biology, Queen's University Belfast, Belfast, UK, 125Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer 
Research, Prevention and Clinical Network (ISPRO), Florence, Italy, 126Department of Preventive Medicine, Seoul National University College of 
Medicine, Seoul, Korea, 127Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea, 128Cancer Research 
Institute, Seoul National University, Seoul, Korea, 129Cancer Research UK Clinical Trials Unit, University of Glasgow, Glasgow, UK, 130Department 
of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 131Department of Epidemiology and 
Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, 132Department of Preventive Medicine, Keck School of Medicine, 
 46 
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA, 133School of Women's and Children's Health, 
Faculty of Medicine, University of NSW Sydney, Sydney, New South Wales, Australia, 134The Kinghorn Cancer Centre, Garvan Institute of Medical 
Research, Sydney, New South Wales, Australia, 135Department of Gynecologic Oncology, Duke University Medical Center, Durham, NC, 
USA, 136Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA, 137Department of Health 
Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA, 138Epidemiology Branch, National Institute of Environmental 
Health Sciences, NIH, Research Triangle Park, NC, USA, 139Department of Preventive Medicine, Keck School of Medicine, University of Southern 
California, Los Angeles, CA, USA, 140Human Genetics Foundation (HuGeF), Turino, Italy, 141Cancer Council Victoria and University of Melbourne, 
Melbourne, Victoria, Australia, 142Gustave Roussy, Villejuif, France, 143Université Paris-Saclay, Université Paris-Sud, Villejuif, 
France, 144Department of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, UK, 145Department of Clinical Pathology, The University 
of Melbourne, Melbourne, Victoria, Australia, 146Division of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, 
USA, 147Epidemiology Center, College of Medicine, University of South Florida, Tampa, FL, USA, 148Division of Breast Cancer Research, The 
Institute of Cancer Research, London, UK, 149Department of Immunology, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, 
Poland, 150Epigenetic and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, 
USA, 151Breast Cancer Research Programme, Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia, 152Department of Surgery, Faculty of 
Medicine, University Malaya, Kuala Lumpur, Malaysia, 153British Columbia's Ovarian Cancer Research (OVCARE) Program - Cheryl Brown Ovarian 
Cancer Outcomes Unit (CBOCOU), BC Cancer Agency, Vancouver, BC, Canada, 154Geisel School of Medicine, Dartmouth College, Hanover, NH, 
USA, 155Cancer Epidemiology Unit, University of Oxford, Oxford, UK, 156Hellenic Health Foundation, Athens, Greece, 157WHO Collaborating 
Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Dept. of Hygiene, Epidemiology and Medical 
Statistics, University of Athens Medical School, Athens, Greece, 158Department of Gynaecology, Radboud University Medical Center, Nijmegen, 
The Netherlands, 159Division of Quantitative Sciences, Department of Obstetrics and Gynecology, Department of Biomedical Informatics, 
Vanderbilt Epidemiology Center, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA, 160Department of 
Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany, 161Biostatistics and Computational Biology Branch, National Institute of 
Environmental Health Sciences, NIH, Research Triangle Park, NC, USA, 162Department of Biomedical Data Science, Stanford University School of 
Medicine, Stanford, CA, USA, 163Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA, 164Department of Surgical 
Sciences, Uppsala University, Uppsala, Sweden, 165Department of Obstetrics and Gynecology, British Columbia's Ovarian Cancer Research 
(OVCARE) Program, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada 
 
PanScan, PANC4 
Demetrius Albanes1, Gabriella Andreotti1, Alan A. Arslan2,3,4, Ana Babic5, Laura Beane-Freeman1, Julie 
Buring6,7, Federico Canzian8, Stephen J. Chanock1, Eric J. Duell9, Charles Fuchs10, J. Michael 
Gaziano6,11,12, Graham G. Giles13,14,15, Edward Giovannucci5, Gary E. Goodman16, Phyllis J. 
Goodman17, Patricia Hartge1, Robert Hoover1, Rudolf Kaaks18, Kay-Tee Khaw19, Eric A. Klein20, Manolis 
Kogevinas21,22,23,24, Charles Kooperberg16, Peter Kraft7,25, Loic Le Marchand26, Núria Malats27, Satu 
Männistö28, Olle Melander29, Roger Milne13,14,30, Kimmie Ng5, Domenico Palli31, Alpa V. Patel32, Ulrike 
Peters16, Miquel Porta22,23, Elio Riboli33, Maria-Jose Sanchez34,35,22, Howard D. Sesso6,7, Xiao-Ou 
Shu36, Mark D. Thornquist16, Anne Tjønneland37,38, Geoffrey S. Tobias1, Ruth C. Travis39, Antonia 
Trichopoulou40, Thérèse Truong41, Roel C.H. Vermeulen42,43, Kala Visvanathan44, Jean Wactawski-
Wende45, Elisabete Weiderpass46, Emily White16,47, Lynne R. Wilkens26, Herbert Yu26, Kai Yu1, Chen 
Yuan5, Anne Zeleniuch-Jacquotte3,48, Wei Zheng36, Jun Zhong49 
 
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA, 2Department of 
Obstetrics and Gynecology, New York University School of Medicine, New York, NY, USA, 3Department of Population Health, New York 
University School of Medicine, New York, NY, USA, 4Department of Environmental Medicine, New York University School of Medicine, New 
York, NY, USA, 5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA, 6Division of Preventive Medicine, Brigham 
and Women’s Hospital, Boston, MA, USA, 7Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA, 8Genomic 
Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany, 9Unit of Nutrition and Cancer, Cancer Epidemiology 
Research Program, Bellvitge Biomedical Research Institute (IDIBELL) , Catalan Institute of Oncology (ICO), Barcelona, Spain, 10Yale Cancer 
Center, New Haven, CT, USA, 11Division of Aging, Brigham and Women’s Hospital, Boston, MA, USA, 12Boston VA Healthcare System, Boston, 
MA, USA, 13Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, VIC, Australia, 14Centre for Epidemiology and 
Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, Australia, 15Department of 
Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia, 16Division of Public Health Sciences, Fred Hutchinson 
Cancer Research Center, Seattle, WA, USA, 17SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 18Division of 
Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, 19Department of Public Health and Primary Care, Institute 
of Public Health, School of Clinical Medicine, University of Cambridge, Cambridge, UK, 20Glickman Urological and Kidney Institute, Cleveland 
Clinic, Cleveland, OH, USA, 21ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, 22CIBER Epidemiología y 
Salud Pública (CIBERESP), Barcelona, Spain, 23Hospital del Mar Institute of Medical Research (IMIM), Universitat Autònoma de Barcelona, 
Barcelona, Spain, 24Universitat Pompeu Fabra (UPF), Barcelona, Spain, 25Department of Biostatistics, Harvard T.H. Chan School of Public Health, 
Boston, MA, USA, 26Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA, 27Genetic and Molecular 
Epidemiology Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain, 28Department of Public Health Solutions, National 
Institute for Health and Welfare, Helsinki, Finland, 29Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden, 30Precision 
 47 
Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia, 31Cancer Risk Factors and Life-Style 
Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Villa delle Rose, Firenze, Italy, 32Epidemiology 
Research Program, American Cancer Society, Atlanta, GA, USA, 33Department of Epidemiology and Biostatistics, School of Public Health, 
Imperial College London, London, UK, 34Andalusian School of Public Health (EASP), Granada, Spain, 35Instituto de Investigación Biosanitaria de 
Granada (ibs.GRANADA), Universidad de Granada, Granada, Spain, 36Division of Epidemiology, Department of Medicine, Vanderbilt 
Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA, 37Diet, Genes and 
Environment, Danish Cancer Society Research Center, Copenhagen, Denmark, 38Department of Public Health, Faculty of Health and Medical 
Sciences, University of Copenhagen, Copenhagen, Denmark, 39Cancer Epidemiology Unit, Nuffield Department of Health, University of Oxford, 
Oxford, UK, 40Hellenic Health Foundation, Athens, Greece, 41INSERM U1018 - Center for Research in Epidemiology and Population Health (CESP), 
Paris-Saclay University, Paris-Sud University, Villejuif, France, 42Institute for Risk Assessment Sciences (IRAS), Division of Environmental 
Epidemiology (EEPI), Utrecht University, Utrecht, The Netherlands, 43Julius Center for Health Sciences and Primary Care, University Medical 
Center Utrech, Utrecht, The Netherlands, 44Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 
USA, 45Department of Epidemiology and Environmental Health, University at Buffalo, Buffalo, NY, USA, 46International Agency for Research on 
Cancer, Lyon, France, 47Department of Epidemiology, University of Washington, Seattle, WA, USA, 48Perlmutter Cancer Center, New York 
University School of Medicine, New York, NY, USA, 49Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, 
National Cancer Institute, National Institutes of Health, Rockville, MD, USA 
 
PRACTICAL, CRUK, BPC3, CAPS, PEGASUS 
Demetrius Albanes1, Australian Prostate Cancer BioResource (APCB)2, Jyotsna Batra2,3, Sara 
Benlloch4, Sonja I. Berndt1, William J. Blot5,6, Hermann Brenner7,8,9, Géraldine Cancel-Tassin10,11, Lisa 
Cannon-Albright12,13, Stephen Chanock1, Frank Claessens14, Judith Clements2,3, David V. Conti15, Cezary 
Cybulski16, Kim De Ruyck17, Jenny L. Donovan18, Manuela Gago-Dominguez19,20, Susan M. 
Gapstur21, Graham G. Giles22,23,24, Eli Marie Grindedal25, Henrik Gronberg26, Freddie C. Hamdy27,28, Robert 
J. Hamilton29,30, Brian E. Henderson15, David J. Hunter31, Sue A. Ingles15, Esther M. John32, Radka 
Kaneva33, Kay-Tee Khaw34, Adam S. Kibel35, Jeri Kim36, Manolis Kogevinas37,38,39,40, Stella Koutros1, Peter 
Kraft31, Davor Lessel41, Yong-Jie Lu42, Christiane Maier43, Florence Menegaux44, Lorelei Mucci45, Kenneth 
Muir46,47, David E. Neal48,49,50, Susan L. Neuhausen51, Lisa F. Newcomb52,53, Børge G. 
Nordestgaard54,55, Hardev Pandha56, Jong Y. Park57, Nora Pashayan58,59, Kathryn L. Penney60, Azad 
Razack61, Elio Riboli62, Monique J. Roobol63, Barry S. Rosenstein64,65, Johanna Schleutker66,67, Karina 
Dalsgaard Sørensen68,69, Janet L. Stanford52,70, Victoria L. Stevens21, Catherine M. Tangen71, Manuel R. 
Teixeira72,73, Stephen N. Thibodeau74, Paul A. Townsend75, Ruth C. Travis76, Nawaid Usmani77,78, Ana 
Vega79, Stephanie Weinstein1, Catharine West80, Fredrik Wiklund26, Alicja Wolk81,82 
 
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA, 2Australian Prostate 
Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of 
Technology, Brisbane, Queensland, Australia, 3Translational Research Institute, Brisbane, Queensland, Australia, 4Department of Public Health 
and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK, 5Department of Medicine, Division of 
Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA, 6International Epidemiology Institute, Rockville, MD, USA, 7Division of 
Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany, 8Division of Preventive Oncology, 
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany, 9German Cancer Consortium 
(DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany, 10CeRePP, Tenon Hospital, Paris, France, 11Sorbonne Universite, GRC n°5, 
ONCOTYPE-URO, Tenon Hospital, Paris, France, 12Department of Medicine, Division of Genetic Epidemiology, University of Utah School of 
Medicine, Salt Lake City, UT, USA, 13George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, USA, 14Department of 
Cellular and Molecular Medicine, Molecular Endocrinology Laboratory, Leuven, Belgium, 15Department of Preventive Medicine, Keck School of 
Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA, 16Department of Genetics and 
Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland, 17Faculty of Medicine and Health Sciences, 
Ghent University, Gent, Belgium, 18School of Social and Community Medicine, University of Bristol, Bristol, UK, 19Genomic Medicine Group, 
Galician Foundation of Genomic Medicine, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario 
Universitario de Santiago, Santiago de Compostela, Spain, 20Moores Cancer Center, University of California San Diego, San Diego, CA, 
USA, 21Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA, 22Cancer Epidemiology Division, Cancer Council Victoria, 
Melbourne, Victoria, Australia, 23Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University 
of Melbourne, Melbourne, Victoria, Australia, 24Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, 
Victoria, Australia, 25Department of Medical Genetics, Oslo University Hospital, Oslo, Norway, 26Department of Medical Epidemiology and 
Biostatistics, Karolinska Institute, Stockholm, Sweden, 27Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK, 28Faculty of 
Medical Science, University of Oxford, John Radcliffe Hospital, Oxford, UK, 29Department of Surgical Oncology, Princess Margaret Cancer Centre, 
Toronto, Canada, 30Department of Surgery (Urology), University of Toronto, Toronto, Canada, 31Department of Epidemiology, Program in 
Genetic Epidemiology and Statistical Genetics, Harvard School of Public Health, Boston, MA, USA, 32Department of Medicine, Division of 
Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA, 33Department of Medical Chemistry and 
Biochemistry, Molecular Medicine Center, Medical University of Sofia, Sofia, Bulgaria, 34Clinical Gerontology Unit Department of Public Health 
and Primary Care, University of Cambridge, Cambridge, UK, 35Division of Urologic Surgery, Brigham and Womens Hospital, Boston, MA, 
 48 
USA, 36Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 37ISGlobal, 
Barcelona, Spain, 38IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain, 39Universitat Pompeu Fabra (UPF), Barcelona, 
Spain, 40CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain, 41Institute of Human Genetics, University Medical Center Hamburg-
Eppendorf, Hamburg, Germany, 42Centre for Molecular Oncology - Barts Cancer Institute - Queen Mary University of London, London, 
UK, 43Humangenetik Tuebingen, Tuebingen, Germany, 44Cancer & Environment Group, Center for Research in Epidemiology and Population 
Health (CESP), Paris-Sud University, Villejuif Cédex, France, 45Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, 
MA, USA, 46Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, UK, 47Warwick 
Medical School, University of Warwick, Coventry, UK, 48Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, 
Oxford, UK, 49Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK, 50Cancer Research UK, Cambridge 
Research Institute, Li Ka Shing Centre, Cambridge, UK, 51Department of Population Sciences, Beckman Research Institute of the City of Hope, 
Duarte, CA, USA, 52Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 53Department of Urology, 
University of Washington, Seattle, WA, USA, 54Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 
Denmark, 55Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark, 56The 
University of Surrey, Guildford, UK, 57Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA, 58Department of Applied 
Health Research, University College London, London, UK, 59Department of Public Health and Primary Care, Department of Oncology, Centre for 
Cancer Genetic Epidemiology, University of Cambridge, Strangeways Laboratory, Cambridge, UK, 60Department of Medicine, Channing Division 
of Network Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA, 61Department of Surgery, Faculty of Medicine, 
University of Malaya, Kuala Lumpur, Malaysia, 62Department of Epidemiology and Biostatistics, School of Public Health, Imperial College 
London, London, UK, 63Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands, 64Department of Radiation 
Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, 65Department of Genetics and Genomic Sciences, Icahn School of 
Medicine at Mount Sinai, New York, NY, USA, 66Institute of Biomedicine, University of Turku, Turku, Finland, 67Department of Medical Genetics, 
Laboratory Division, Turku University Hospital, Turku, Finland, 68Department of Molecular Medicine, Aarhus University Hospital, Aarhus, 
Denmark, 69Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, 70Department of Epidemiology, The University of Washington 
School of Public Health, Seattle, WA, USA, 71SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 72Department 
of Genetics, Portuguese Oncology Institute of Porto, Porto, Portugal, 73Biomedical Sciences Institute (ICBAS), University of Porto, Porto, 
Portugal, 74Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA, 75Division of Cancer Sciences, NIHR 
Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK, 76Nuffield 
Department of Population Health, Cancer Epidemiology Unit, University of Oxford, Oxford, UK, 77Department of Oncology, Cross Cancer 
Institute, University of Alberta, Edmonton, Alberta, Canada, 78Division of Radiation Oncology, Cross Cancer Institute, University of Alberta, 
Edmonton, Alberta, Canada, 79Fundación Pública Galega de Medicina Xenómica-SERGAS, Santiago de Compostela, Spain, 80Division of Cancer 
Sciences, Manchester Academic Health Science Centre, University of Manchester, The Christie Hospital NHS Foundation Trust, Manchester, 
UK, 81Division of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 82Department of 
Surgical Sciences, Uppsala University, Uppsala, Sweden 
 
Renal Cancer GWAS 
Demetrius Albanes1, Garnet L. Anderson2, Gabriella Andreotti1, John G. Anema3, Rosamonde E. 
Banks4, Poulami Barman5, Laura E. Beane Freeman1, Vladimir Bencko6, Simone Benhamou7, Celine 
Besse8, Amanda Black1, Helene Blanche9, Anne Boland8, Kevin M. Brown1, Fiona Bruinsma10, H.B. Bueno-
De-Mesquita11, Laurie Burdette1, Julie Buring12, Geraldine Cancel-Tassin13, Frederico Canzian14, Hallie 
Carol15, Robert Carreras-Torres16, Eunyoung Cho17, Toni K. Choueiri15, Wong-Ho Chow18, Peter E. 
Clark19, Leandro M. Colli1, Olivier Cussenot13, Cezary Cybulski20, Jean-Francois Deleuze21,9, Eric J. 
Duell22, Todd E. Edwards19, Timothy Eisen23, Eleonora Fabianova24, Tony Fletcher25, Matthieu 
Foll16, Lenka Foretova26, Matthew L. Freedman15, Neal D. Freedman1, Valerie Gaborieau16, Susan M. 
Gapstur27, J Michael. Gaziano28, Marc Henrion29, Jonathan N. Hofmann1, Ivana Holcatova6, Wen-Yi 
Huang1, Kristian Hveem30, Vladimir Janout31, Viorel Jinga32, Mattias Johansson16, Lisa Johnson2, Susan 
Jordan33, Richard J. Kahnoski3, Kvetoslava Koppova24, Stella Koutros1, Brian R. Lane3, James 
Larkin34, Susanna C. Larsson35, G Mark. Lathrop36, I-Min Lee12, Bradley C. Leibovich5, Peng Li16, Loren 
Lipworth19, Jolanta Lissowska37, Börje Ljungberg38, Jan Lubinski20, Juhua Luo39, Mitchell J. Machiela1, Satu 
Mannisto40, Dana Mates41, Mirjana Mijuskovic42, Lee E. Moore1, Anush Mukeriya43, Marie 
Navratilova26, Sabrina L. Noyes44, Miodrag Ognjanovic45, David Petillo44, Mark M. Pomerantz15, Mark A. 
Preston28, Egor Prokhortchouk46, Stefan Rascu32, Peter Rudnai47, Joshua N. Sampson1, Sharon A. 
Savage1, Peter J. Selby4, Howard S. Sesso12, Gianluca Severi7, Raviprakash T. Sitaram38, Konstantin G. 
Skryabin46, Victoria L. Stevens27, Neonila Szeszenia-Dabrowska48, Bin Tean Teh44, Lars J. 
Vatten49, Zhaoming Wang50, Stephanie Weinstein1, Emily White2, Kathryn M. Wilson12, Alicja 
Wolk35, Christopher Wood18, Yuanqing Ye18, Meredith Yeager1, David Zaridze43 
 
 49 
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA, 2Fred Hutchinson 
Cancer Research Center, Seattle, WA, USA, 3Division of Urology, Spectrum Health, Grand Rapids, MI, USA, 4University of Leeds, Leeds, 
UK, 5Department of Urology, Mayo Clinic, Rochester, MN, USA, 6Charles University, Prague, Czech Republic, 7INSERM, Villejuif, France, 8Centre 
National de Genotypage, Evry, France, 9Fondation Jean Dausset-Centre d'Etude du Polymorphisme Humain, Paris, France, 10Cancer 
Epidemiology Division, Cancer Council Victoria, Melbourne, Australia, 11National Institute forPublic Health and the Environment, Bilthoven, The 
Netherlands, 12Harvard T.H. Chan School of Public Health, Boston, MA, USA, 13Groupe de Recherche GRC-UPMC n°5, Centre de Recherche sur 
les Pathologies Prostatiques et Urologiques (CeRePP), Paris, France, 14Genomic Epidemiology Group, German Cancer Research Center, 
Heidelberg, Germany, 15Dana-Farber Cancer Institute, Boston, MA, USA, 16International Agency for Research on Cancer (IARC), Lyon, 
France, 17Brown University, Providence, RI, USA, 18Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, 
TX, USA, 19Vanderbilt-Ingram Cancer Center, Nashville, TN, USA, 20Pomeranian Medical University, Szczecin, Poland, 21Centre National de 
Genotypage, Institut de Genomique, Centre de l'Energie Atomique et aux Energies Alternatives, Paris, France, 22Catalan Institute of Oncology, 
Barcelona, Spain, 23University of Cambridge, Cambridge, UK, 24Regional Authority of Public Health in Banska Bystrica, Banska Bystrica, 
Slovakia, 25London School of Hygiene and Tropical Medicine, University of London, London, UK, 26Department of Cancer Epidemiology and 
Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic, 27American Cancer Society, Atlanta, GA, USA, 28Brigham and Women's 
Hospital, Boston, MA, USA, 29Icahn School of Medicine at Mount Sinai, New York, NY, USA, 30Norwegian University of Science and Technology, 
Levanger, Sweden, 31Palacky University, Olomouc, Czech Republic, 32Carol Davila University of Medicine and Pharmacy, Bucharest, 
Romania, 33QIMR Berghofer Medical Research Institute, Brisbane, Australia, 34The Institute for Cancer Research, London, UK, 35Institute of 
Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 36Genome Quebec Innovation Centre, McGill University, Montreal, 
Canada, 37The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland, 38Umeå University, Umeå, Sweden, 39Department 
of Epidemiology and Biostatistics, School of Public Health Indiana University, Bloomington, IN, USA, 40National Institute for Health and Welfare, 
Helsinki, Finland, 41National Institute of Public Health, Bucharest, Romania, 42Military Medical Academy, Belgrade, Serbia, 43Russian N.N. Blokhin 
Cancer Research Centre, Moscow, Russia, 44Van Andel Research Institute, Grand Rapids, MI, USA, 45International Organization for Cancer 
Prevention and Research, Belgrade, Serbia, 46Centre ‘Bioengineering’ of the Russian Academy of Sciences, Moscow, Russia, 47National Public 
Health Center, National Directorate of Environmental Health, Budapest, Hungary, 48Department of Epidemiology, Institute of Occupational 
Medicine, Lodz, Poland, 49Norwegian University of Science and Technology, Trondheim, Norway, 50St. Jude Children's Research Hospital, 
Memphis, TN, USA 
 
TECAC 
Victoria Cortessis1, Jourik A. Gietema2, Ramneek Gupta3, Trine B. Haugen4, Michelle A.T. 
Hildebrandt5, Robert Karlsson6, Kevin Litchfield7, Nandita Mitra8, Ewa Rajpert-De Meyts9, Stephen M. 
Schwartz10, Rolf I. Skotheim11, Saran Vardhanabhuti12, Zhaoming Wang13 
 
1Department of Preventive Medicine, University of Southern California, Los Angeles, USA, 2Department of Medical Oncology, University Medical 
Center Groningen, Groningen, The Netherlands, 3Department of Health Technology, Technical University of Denmark, Lyngby, Denmark, 4Health 
Sciences, Oslo and Akershus University College of Applied Sciences, Oslo, Norway, 5Department of Epidemiology, MD Anderson Cancer Center, 
Houston, USA, 6Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Solna, Sweden, 7Cancer Evolution and Genome 
Instability Laboratory, The Francis Crick Institute, London, UK, 8Department of Biostatistics, Epidemiology and Informatics, University of 
Pennsylvania, Philadelphia, USA, 9Department of Growth and Reproduction, Copenhagen University Hospital (Rigshospitalet), Copenhagen, 
Denmark, 10Epidemiology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, USA, 11Department of 
Cancer Prevention, Genome Biology Group, Institute for Cancer Research, Oslo, Norway, 12Department of Biostatistics, Harvard T.H. Chan 






1. Berndt, S. I. et al. Meta-analysis of genome-wide association studies discovers multiple loci for 
chronic lymphocytic leukemia. Nat Commun 7, 10933 (2016). 
2. Gharahkhani, P. et al. Genome-wide association studies in oesophageal adenocarcinoma and 
Barrett’s oesophagus: a large-scale meta-analysis. Lancet Oncol 17, 1363-1373 (2016). 
3. Wang, Z. et al. Meta-analysis of five genome-wide association studies identifies multiple new loci 
associated with testicular germ cell tumor. Nat Genet 49, 1141-1147 (2017). 
4. Lesseur, C. et al. Genome-wide association analyses identify new susceptibility loci for oral cavity 
and pharyngeal cancer. Nat Genet 48, 1544-1550 (2016). 
5. Klein, A. P. et al. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic 
cancer. Nat Commun 9, 556 (2018). 
6. Scelo, G. et al. Genome-wide association study identifies multiple risk loci for renal cell carcinoma. 
Nat Commun 8, 15724 (2017). 
7. Melin, B. S. et al. Genome-wide association study of glioma subtypes identifies specific differences 
in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet 49, 789-794 
(2017). 
8. Law, M. H. et al. Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous 
malignant melanoma. Nat Genet 47, 987-995 (2015). 
9. Schumacher, F. R. et al. Genome-wide association study of colorectal cancer identifies six new 
susceptibility loci. Nat Commun 6, 7138 (2015). 
10. O’Mara, T. A. et al. Identification of nine new susceptibility loci for endometrial cancer. Nat 
Commun 9, 3166 (2018). 
11. Phelan, C. M. et al. Identification of 12 new susceptibility loci for different histotypes of epithelial 
ovarian cancer. Nat Genet 49, 680-691 (2017). 
12. McKay, J. D. et al. Large-scale association analysis identifies new lung cancer susceptibility loci and 
heterogeneity in genetic susceptibility across histological subtypes. Nat Genet 49, 1126-1132 
(2017). 
13. Schumacher, F. R. et al. Association analyses of more than 140,000 men identify 63 new prostate 
cancer susceptibility loci. Nat Genet 50, 928-936 (2018). 
14. Michailidou, K. et al. Association analysis identifies 65 new breast cancer risk loci. Nature 551, 92-
94 (2017). 
 
